US20020176850A1 - Immunotherapy of cancer with allogeneic lymphocytes - Google Patents
Immunotherapy of cancer with allogeneic lymphocytes Download PDFInfo
- Publication number
- US20020176850A1 US20020176850A1 US10/005,747 US574701A US2002176850A1 US 20020176850 A1 US20020176850 A1 US 20020176850A1 US 574701 A US574701 A US 574701A US 2002176850 A1 US2002176850 A1 US 2002176850A1
- Authority
- US
- United States
- Prior art keywords
- patient
- cells
- hla
- compatible
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000735 allogeneic effect Effects 0.000 title claims abstract description 107
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 55
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 201000011510 cancer Diseases 0.000 title claims abstract description 14
- 238000009169 immunotherapy Methods 0.000 title description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 193
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 67
- 102000004127 Cytokines Human genes 0.000 claims abstract description 49
- 108090000695 Cytokines Proteins 0.000 claims abstract description 49
- 238000001727 in vivo Methods 0.000 claims abstract description 37
- 230000003211 malignant effect Effects 0.000 claims abstract description 37
- 210000000130 stem cell Anatomy 0.000 claims abstract description 29
- 230000036755 cellular response Effects 0.000 claims abstract description 15
- 230000011132 hemopoiesis Effects 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 230000004044 response Effects 0.000 claims description 28
- 210000001185 bone marrow Anatomy 0.000 claims description 26
- 208000032839 leukemia Diseases 0.000 claims description 21
- 210000000265 leukocyte Anatomy 0.000 claims description 20
- 238000012544 monitoring process Methods 0.000 claims description 20
- 210000005259 peripheral blood Anatomy 0.000 claims description 16
- 239000011886 peripheral blood Substances 0.000 claims description 16
- 238000002054 transplantation Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 239000005022 packaging material Substances 0.000 claims description 6
- 230000003836 peripheral circulation Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 claims description 2
- 208000007660 Residual Neoplasm Diseases 0.000 abstract description 18
- 238000000338 in vitro Methods 0.000 abstract description 15
- 230000036961 partial effect Effects 0.000 abstract description 9
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000009876 antimalignant effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 61
- 208000024908 graft versus host disease Diseases 0.000 description 61
- 208000009329 Graft vs Host Disease Diseases 0.000 description 57
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 40
- 210000002798 bone marrow cell Anatomy 0.000 description 40
- 238000010322 bone marrow transplantation Methods 0.000 description 32
- 208000004736 B-Cell Leukemia Diseases 0.000 description 29
- 108010002350 Interleukin-2 Proteins 0.000 description 23
- 102000000588 Interleukin-2 Human genes 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 229960004397 cyclophosphamide Drugs 0.000 description 21
- 230000003750 conditioning effect Effects 0.000 description 20
- 210000004989 spleen cell Anatomy 0.000 description 19
- 238000010254 subcutaneous injection Methods 0.000 description 18
- 239000007929 subcutaneous injection Substances 0.000 description 18
- 238000001802 infusion Methods 0.000 description 16
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 15
- 210000001165 lymph node Anatomy 0.000 description 13
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 12
- 229960001196 thiotepa Drugs 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 8
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 8
- 229960003459 allopurinol Drugs 0.000 description 8
- 229960002092 busulfan Drugs 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 8
- 229960005420 etoposide Drugs 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 229960001924 melphalan Drugs 0.000 description 8
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000004820 blood count Methods 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000000704 Interleukin-7 Human genes 0.000 description 5
- 108010002586 Interleukin-7 Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 229950000547 mafosfamide Drugs 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000004214 philadelphia chromosome Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Definitions
- This invention relates to methods of eradicating residual tumor cells following surgical intervention, chemotherapy and/or radiotherapy.
- the methods involve autologous bone marrow transplantation followed by administration of allogeneic peripheral blood leukocytes. More particularly, this invention relates to use of HLA-compatible allogeneic peripheral blood lymphocytes (PBL), following autologous bone marrow and/or peripheral blood stem cell transplantation, to induce a graft-versus-malignant cell response. Such a response is instrumental in prevention of disease relapse.
- PBL peripheral blood lymphocytes
- Bone marrow transplantation makes it possible to administer to patients with resistant disease high, “supra-lethal,” combinations of chemotherapy and radiation, ignoring the irreversible toxicity of such therapeutic combinations on the normal bone marrow compartment. Nevertheless, such “debulking” of a patient's tumor(s) can leave a fraction of residual malignant cells that may lead to disease relapse.
- relapse rates in patients with acute leukemia or chronic myeloid leukemia reconstituted by bone marrow grafts obtained from an identical twin are significantly higher than in those reconstituted by bone marrow cells obtained from an HLA-identical but non-syngeneic sibling. Ringden and Horowitz, Transplant. Proc. 21: 2989-92 (1989).
- relapse rates following transplantation of the patient's own (autologous) marrow even following adequate purging in vitro for elimination of residual leukemia cells, are significantly higher than following allogeneic BMT. Armitage, Curr. Opinion in Hematol. 1993: 240-45 (1993).
- Allogeneic donor cells may also play a role against lymphoma, as shown in experimental animals, Slavin et al., Cancer Immunol. Immunother. 11: 155-58 (1981), and humans. Phillips et al., J. Clin. Oncol. 4: 480-88 (1986); Ernst et al., Proc. of the 4th International Conference on Lymphoma, Lugano 1990, Abstract #P35; Chopra et al., J. Clin. Oncol. 10: 1690-95 (1992). As shown in experimental animals, graft-versus-tumor effects (GVT), similar to graft-versus-leukemia effects (GVL), may occur following BMT, independently of GVHD. Moscovitch and Slavin, J. Immunol. 132: 997-1000 (1984).
- GVT graft-versus-tumor effects
- VTL graft-versus-leukemia effects
- GVHD-associated anti-leukemia effector mechanisms may be of benefit in BMT, nevertheless GVHD represents one of the major obstacles in allogeneic- BMT, even among perfectly HLA-matched siblings.
- Acute GVHD develops in the majority of recipients of allogeneic BMT, with clinically significant manifestations in 26-64% of the recipients despite optimal post-transplant immunosuppressive prophylaxis. Storb et al., Blood 73: 1729 (1989).
- Chronic GVHD may occur in up to 45% of long term survivors.
- There is no satisfactory therapy for patients with established GVHD and hence patients with severe manifestations of acute or chronic forms of the disease are prone to develop multisystem complications that may require frequent hospitalizations, leading to poor quality of life and occasionally serious or even fatal complications.
- GVHD following allogeneic BMT can be prevented by adequate pretransplant T-lymphocyte depletion, using no post-transplant anti-GVHD prophylaxis.
- Reisner et al. In: Slavin, S (ed.), Tolerance in Bone Marrow and Organ Transplantation . Elsevier, Amsterdam (1984), p. 293 ; Waldmann et al., Lancet 2: 483-85 (1984); Slavin et al., Transplant. Proc. 17: 465-67 (1985).
- BMT without GVHD represents a better tolerated procedure that may necessitate shorter hospitalization with superior subjective immediate outcome following allogeneic BMT.
- the quality of life of long-term survivors without GVHD is clearly better than for those patients with severe acute or chronic GVHD.
- the present invention includes a method of treating a human cancer patient who has undergone a malignant cell debulking regimen.
- the patient is considered to be at risk for disease relapse due to a population of residual malignant cells that may remain viable in the patient following the debulking procedure.
- a sample of stem cells, taken from the patient is obtained and determined to be suitable for autologous transplantation into the patient. This sample is used to perform an autologous transplant of the patient, i.e, infusing the patient's stem cells back into the patient. The patient is then monitored until the patient is partially hematopoiesis recovered but is not fully immune-reconstituted.
- the patient is administered an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a clinically significant graft-versus-malignant cell response.
- the patient is then monitored for levels of malignant cells deriving from any residual malignant cells that might have been present following the original debulking procedure.
- This monitoring may constitute one or more molecular or cellular assays to detect or quantify malignant cells, may constitute a monitoring program to detect clinical signs of relapse, or any combination of these monitoring methods.
- a clinically significant response permits, for example, the patient to avoid relapse, substantially prolongs the time to relapse or otherwise engenders a beneficial condition that significantly prolongs life.
- a graft-versus malignant cell response is not clinically significant unless there is some clinical benefit to the patient.
- Evidence for a clinically significant response may include, for example, absence or delay of relapse, evidence for elimination of minimal residual disease, i.e., elimination of disease-specific markers or, where appropriate, elimination of markers directed to host-specific cells.
- the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- step (a) above can be augmented by administering, concomitant with the allogeneic lymphocytes, at least one T-cell-activating cytokine to the patient. Since the T-cell-activating cytokine is administered directly to the patient, the infused allogeneic lymphocytes are exposed to the cytokine in vivo.
- the present invention also includes an alternative method of treating a human cancer patient who has undergone a malignant cell debulking regimen.
- the patient is considered to be at risk for disease relapse due to a population of residual malignant cells that may remain viable in the patient following the debulking procedure.
- a sample of stem cells, taken from the patient is obtained and determined to be suitable for autologous transplantation into the patient. This sample is used to perform an autologous transplant of the patient, i.e, infusing the patient's stem cells back into the patient. The patient is then monitored until the patient is partially hematopoiesis recovered but is not fully immune-reconstituted.
- the patient is administered an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a mild graft-versus-host response.
- the patient is then monitored, as above, for levels of malignant cells deriving from any residual malignant cells that might have been present following the original debulking procedure.
- graft-versus-host response includes but is not limited to the classic clinical symptoms of graft-versus host disease (GVHD), known to those having ordinary skill in the art.
- graft-versus-host response also includes molecular or cellular responses that correlate with the clinical symptoms of GVHD or with the impending onset of the clinical symptoms of GVHD.
- the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- step (a) above can be augmented by administering, concomitant with the allogeneic lymphocytes, at least one T-cell-activating cytokine to the patient. Since the T-cell-activating cytokine is administered directly to the patient, the infused allogeneic lymphocytes are exposed to the cytokine in vivo.
- the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- CAL may be given in the initial infusion.
- the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- the cytokine can be, without limitation, any one or more of the following: interleukin 2 (IL2), interleukin 4 (IL4), interleukin 5 (IL5), interleukin 6 (IL6), interleukin 7 (IL-7), interferon alpha (IFN ⁇ ), interferon gamma (IFN ⁇ ) and tumor necrosis factor (TNF ⁇ ).
- IL2 interleukin 2
- IL4 interleukin 4
- IL5 interleukin 5
- IL6 interleukin 6
- IL-7 interleukin 7
- IFN ⁇ interferon alpha
- IFN ⁇ interferon gamma
- TNF ⁇ tumor necrosis factor
- Any of these cytokines can be a native factor obtained from natural sources, a factor produced by recombinant DNA methodology, a chemically synthesized polypeptide or other molecule, or any derivative having the functional activity of the native factor.
- the stem cells used in the above-described methods may be obtained from bone marrow, from the peripheral circulation, or, where appropriate, from fetal sources such as fetal tissue, fetal circulation and umbilical cord blood.
- Cancer patients treatable with the methods of the present invention are any patients having a pathological condition caused by malignant cells, including without limitation leukemia, lymphoma, and breast cancer.
- the HLA-compatible allogeneic cells employed in the present invention preferably are fully HLA-matched with the patient. Alternatively the allogeneic cells may be at least haploidentical with the patient. If the allogeneic cells are derived from a sibling of the patient, the cells preferably are fully HLA matched with the patient, although some mismatch may be tolerated.
- the allogeneic cells from a sibling to the patient may, in some cases, be single HLA locus-mismatched. If the allogeneic cells are derived from an unrelated individual, preferably the cells are fully HLA matched with the patient.
- the present invention further includes an article of manufacture comprising packaging material and a biological cell container within the packaging material.
- the packaging material contains a label or package insert indicating that the biological cell container, and/or any contents therein, are to be used in any of the above-described methods for treating a human cancer patient.
- FIG. 2 depicts the results of adoptive transfer of spleen cells obtained from lethally irradiated F1 mice reconstituted with 10 7 syngeneic bone marrow cells mixed with 10 5 BCL1 cells.
- A, n 10 6
- C 10 ⁇ 10 6
- D 30 ⁇ 10 6
- FIG. 3 depicts results of adoptive transfer of spleen cells obtained from BALB/c mice treated with cyclophosphamide (300 mg/kg IP), inoculated 24 hours later with 10 3 BCL1 cells, and one day later receiving 4 ⁇ 10 6 syngeneic, ASTA-Z-treated bone marrow cells.
- the present inventor has employed allogeneic peripheral blood lymphocytes, alone or in combination with cytokine treatment in vivo or in vitro, for successful elimination of minimal residual disease following chemotherapy and/or radiotherapy.
- Appropriate treatment regimens have been circumscribed by studies in laboratory animals, and the treatment protocols have been further extended to human patients at high risk for disease relapse.
- MRD minimal residual disease
- tumor as used herein includes all pathological conditions involving malignant cells; this can include “solid” tumors arising in solid tissues or organs as well as “liquid” tumors such as leukemias and lymphomas deriving from malignant transformation of hematopoietic cells.
- ABMT autologous bone marrow transplantation
- an individual receives his or her own bone marrow cells by infusion following a tumor debulking procedure.
- the bone marrow cells are taken from the patient and preserved, for example by cryopreservation, prior to the debulking procedure.
- an otherwise lethal debulking regimen e.g., chemotherapy or radiotherapy that severely damages or destroys the patient's bone marrow.
- the patient's bone marrow is reconstituted by stem cells present in the preserved sample of bone marrow.
- Stem cells capable of reconstituting a patient's immune system can be obtained not only by direct extraction from the bone marrow, but also from the patient's peripheral circulation following mobilization of such cells from the bone marrow. This can be accomplished by treatment of the patient with granulocyte colony stimulating factor (G-CSF) or other appropriate factors that induce movement of stem cells from the bone marrow into the peripheral circulation. Following-mobilization, the stem cells can be collected from peripheral blood by any appropriate cell apheresis technique, for example through use of a commercially available blood cell collection device as exemplified by the CS 3000® Plus blood cell collection device marketed by the Fenwal Division of Baxter Healthcare Corporation.
- G-CSF granulocyte colony stimulating factor
- PBSC peripheral blood stem cells
- ASCT autologous stem cell transplantation
- mice that simulates ASCT in humans. This is done through use of stem cell donors and recipients derived from a syngeneic strain of mice. In such strains, inbreeding has created a situation in which, for practical purposes, mice within the strain are genetically identical to each other. Such mice accept tissues and organs transplanted between individuals without evidence of immune rejection, in a manner analogous to acceptance of a patient's own cells following ASCT. Transplantation of bone marrow-derived stem cells between such mice is referred to herein as “syngeneic bone marrow transplantation” (SBMT) and should be considered analogous to ABMT and ASCT in humans.
- SBMT syngeneic bone marrow transplantation
- mice received a lethal dose of total body irradiation (TBI) or, alternatively, a lethal dose of cyclophosphamide administered intraperitoneally.
- Bone marrow cells BMC were extracted directly from the bone marrow of syngeneic mice.
- these BMC preparations were treated with mafosfamide (ASTA-Z) to simulate a “purging” procedure in which the patient's stem cells, prior to ASCT, are treated to remove or destroy at least a fraction of any contaminating malignant cells.
- ASCT mafosfamide
- the mice received 10 7 syngeneic bone marrow cells by infusion into the lateral tail vein.
- 10 5 BCL1 tumor cells were added to the syngeneic BMC prior to SBMT.
- Allo-CMI allogeneic cell-mediated immunotherapy
- Allo-CCI allogeneic cell-mediated cytokine-activated immunotherapy
- Allo-CMI involved transfer of immunocompetent allogeneic lymphocytes (i.e., lymphocytes from a mouse strain other than that of the recipient mice) at various times and at various doses, administered post-SBMT. Generally these lymphocytes represented peripheral blood lymphocytes (PBL) or mixtures of donor spleen and lymph node cells.
- Allo-CCI involved transfer of allogeneic lymphocytes pre-activated in vitro with recombinant human interleukin 2 (rhIL2).
- CAL refers to such “cytokine-activated lymphocytes.”
- Allo-CMI or Allo-CCI regimen was accompanied by simultaneous in vivo administration of rhIL2 to the recipient mice, in order to facilitate additional activation of the infused lymphocytes in vivo.
- mice have been adapted to human patients in a variety of protocols undertaken by the present inventor in treating cancer patients at high risk of disease relapse.
- Cancer patients having acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma and metastatic breast cancer have been treated with the methods of the present invention.
- Allogeneic cells preferably are chosen from human leukocyte antigen (HLA)-compatible donors.
- HLA-compatible lymphocytes may be taken from a fully HLA-matched relative such as a parent, brother or sister.
- donor lymphocytes may be sufficiently HLA-compatible with the recipient to obtain the desired result even if a sibling donor is single-locus mismatched. If a donor is unrelated to the recipient, preferably the donor lymphocytes are fully HLA matched with the recipient.
- an initial dose of at least about 10 7 HLA-compatible allogeneic lymphocytes/kg is given once the patient has achieved a clinically stable condition (e.g., stabilized blood counts).
- the patient is also administered cytokine in vivo concomitant with administration of the HLA-compatible lymphocytes,.
- the cytokine is rhIL2 at a dose of about 6 ⁇ 10 6 IU of rhIL2/m 2 /day, by subcutaneous injection, beginning on the same day as infusion of the allogeneic lymphocytes.
- Other appropriate cytokines may be used alone or in combination with rhIL2, as long as the desired enhancing effect is obtained.
- additional cytokines include, without limitation, native or recombinant forms of IL6, IL7 and alpha and gamma-interferon (INF ⁇ , INF ⁇ , respectively).
- GVHD fails to develop in a patient given these numbers of HLA-compatible allogeneic lymphocytes with concomitant in vivo cytokine
- the treatment regimen is escalated. Preferably this is done by administering a second dose of allogeneic HLA-compatible lymphocytes preactivated in vitro with cytokine.
- the cytokine is rhIL2, although other appropriate cytokines may be used alone or in combination with rhIL2, as long as the desired activation in vitro is obtained.
- additional cytokines include, without limitation, native or recombinant forms of IL6, IL7 and alpha-interferon (INF ⁇ ), alone or in combination with IL2.
- cyclophosphamide or other appropriate immunosuppressants may be administered to the patient to avoid rejection of the second dose of cells. That is, the immunosuppressant is given in a dose effective for killing host T cells that might otherwise operate to reject the second allogeneic inoculum; the immunosuppressant may have the added benefit of eliminating potential host suppressor cell functions that can interfere with the GVT effects of the infused CAL.
- in vivo cytokine is administered to the patient concomitant with the second dose of cells (CAL).
- any combination of allogeneic peripheral blood lymphocytes, in vivo cytokine and/or CAL is covered by the present invention, so long as the initial dose of cells is capable of eliciting a beneficial GVT response.
- This dose of cells corresponds to a number of HLA-compatible allogeneic peripheral blood lymphocytes that elicits a host response beyond mere immunization to a second dose of cells from the same or similar donor. Generally, this number corresponds to at least about 10 7 allogeneic peripheral blood lymphocytes/kg. However, it is possible that a lower dose of cells, e.g., about 10 5 cells/kg, could be used if, for example, CAL were used for the initial infusion.
- the patient may be monitored for levels of malignant cells, i.e., for evidence of minimal residual disease. Such monitoring may comprise patient follow-up for clinical signs of relapse.
- the monitoring may also include, where appropriate, various molecular or cellular assays to detect or quantify any residual malignant cells. For example, in cases of sex-mismatched donors and recipients, residual host-derived cells may be detected through use of appropriate sex markers such as Y chromosome-specific nucleic acid primers or probes.
- PCR polymerase chain reaction
- appropriate molecular markers specific for tumor cells can be employed.
- nucleic acid primers and/or probes specific for the bcr/abl translocation in chronic myelogenous leukemia, for other oncogenes active in various tumors, for inactivated tumor suppressor genes, other tumor-specific genes, or any other assay reagents known to be specific for tumor cells may be employed. Any of these or functionally comparable procedures may be used to monitor the patient for evidence of residual malignant cells.
- irradiated blood products when such products are required by the patient. These products are irradiated in order to avoid the possibility of engraftment of immunocompetent T-lymphocytes derived from the donor's blood product (e.g., platelets or red blood cells). In most institutions, irradiated blood products are also used for patients receiving high dose conventional chemotherapy without transplant, e.g., blood products given following induction of remission in leukemia and lymphoma patients. Obviously, the chances for engraftment of immunocompetent T-lymphocytes from otherwise mismatched blood products is relatively small under normal circumstances. However, if immunosuppression is sufficient to permit engraftment, GVHD can be “stormy” and lethal.
- non-irradiated donor-type lymphocytes are used intentionally for induction of graft-versus-malignant cell effects.
- the methods are structured to produce transient engraftment, so as to induce graft-versus-malignant cell effects that may be accompanied by mild GVHD.
- the donor cells used in the Allo-CMI and Allo-CCI procedures are HLA-compatible with the recipient, chances of engraftment are better than if the donor's cells were not functionally matched with the patient's major histocompatibility complex.
- the chance of immediate rejection on the one hand and lethal GVHD on the other hand are relatively small because of the HLA compatibility.
- the Allo-CMI/CCI protocols of the present invention provide the possibility for transient engraftment of donor's PBL with effective GVT and with a minimal chance for induction of severe GVHD.
- BALB/c mice and C57BL/6 (C57), (BALB/c x C57BL/6)F1 (F1) mice, 2-6 months old, were purchased from the breeding colony of the Hebrew University-Hadassah Medical School, Jerusalem. Mice were kept under standard conditions, with acidic water (pH 2.7) and no special protective measures. Mice were given 0.5% neomycin sulfate in their drinking water for 2 weeks post-transplantation.
- B Murine B-Cell Leukemia (BCL1).
- BCL1 a spontaneous, transplantable B-cell leukemia/lymphoma of BALB origin is characterized by marked (up to 50 fold) splenomegaly, accompanied by extreme peripheral blood lymphocytosis (>200,00/mm 3 ) and results in death of all mice inoculated with >10-100 tumor cells. Slavin et al., Nature 272: 624 (1978); Slavin et al., Cancer Res. 41: 4162 (1981). BCLI was maintained in vivo in BALB mice by IV passage of 10 6 -10 7 peripheral blood lymphocytes (PBL) obtained from tumor bearing mice. Mice with marked lymphocytosis in the blood were subsequently used as BCL1 cell donors for experimental mice. PBL counts for all experimental groups were carried out weekly. Leukemia was defined as PBL counts exceeding 20,000/mm 3 . At the peak of disease PBL counts usually reached >100,000/mm 3 .
- ASTA-Z was kindly provided by Drs M. Peukert and H. Sindermann (Astawerke, Bielefeld, Germany) as a lyophilized powder and was freshly dissolved in saline before use. ASTA-Z has been employed in vitro to reduce or eliminate malignant cell populations from bone marrow preparations. Douay et al., CR Acad. Sci. Paris t. 301, Ser III, no. 3:1 (1985).
- mice were exposed to a single dose of 750 cGy total body irradiation (TBI) from a Philips X-ray unit (250 kV 20 mA) with a focus to skin distance of 70 cm at a dose rate of 60 cGy/min.
- mice were conditioned with freshly dissolved cyclophosphamide (CY) (300 mg/kg) (Taro, Israel) given intraperitoneally (IP). Twenty-four hours later, mice received 10 7 syngeneic marrow cells via the lateral tail vein.
- BMC Bone Marrow Cells
- BMC were obtained from the femura, tibiae and humera of syngeneic mice. Mononuclear cells containing 10 7 BMC in 0.25 ml Hank's medium were injected into the lateral tail vein of recipients 24 hours post-radiation.
- rhIL2 provided as 1 mg Proleukin (3 ⁇ 10 6 Cetus Units, equivalent to 18 ⁇ 10 6 International Units) was kindly supplied by Dr. S. L. Aukerman, Cetus/Chiron, Calif., USA. rhIL2 was initially diluted with water for injection and subsequently rediluted with dextrose 5%. International units (IU) are used throughout the remainder of the present application.
- BMC were cultured in 225 cm 3 flasks (Corning 25160-225, Corning Glass, Corning N.Y.) in RPMI 1640 medium (Beit Haemek, Israel) containing L-glutamine, non-essential amino acids, pyruvate, 10% bovine calf serum (BCS) and rhIL2 (6,000 IU/ml) for 4 days in a humidified incubator with 5% CO 2 at 37° C. Following harvesting, viability was determined by the trypan blue exclusion method.
- Allogeneic cell-mediated immunotherapy consisted of adoptive transfer of immunocompetent allogeneic lymphocytes (PBL or a mixture of donor spleen and lymph node cells) as detailed in the results for each experiment, below.
- Allogeneic cell-mediated cytokine-activated immunotherapy (Allo-CCI) consisted of adoptive transfer of allogeneic lymphocytes pre-activated in vitro with rhIL2 (allogeneic “CAL”) In some experiments allogeneic lymphocyte infusion was followed by subsequent in vivo activation with rhIL2, by additional Allo-CMI with in vivo rhIL-2, or by additional Allo-CCI with in vivo rhIL-2, respectively.
- F1 mice were lethally irradiated (750 cGy) and transplanted with 10 7 syngeneic BMC. Following inoculation of 10 5 BCL1 cells to simulate MRD, varying numbers of C57 PBL were administered intravenously to induce GVL-like effects through allo-CMI. In order to detect the efficacy of allo-CMI in eradicating residual BCL1 cells, aliquots of 10 5 spleen cells pooled from 2-3 experimental mice were adoptively transferred to secondary normal BALB recipients, one or two weeks post-SBMT.
- FIG. 1 summarizes results obtained from three different experiments in a total of 120 mice. Injection of 20-30 ⁇ 10 6 PBL, obtained from C57 mice to induce allo-CMI after SBMT in F1 recipients, effectively eliminated residual BCL1 cells, as none of 40 secondary adoptive BALB recipients developed leukemia (>180 days). In contrast, leukemia developed in all 20 secondary BALB recipients inoculated with 10 5 spleen cells obtained from Fl recipients that had received 20-30 ⁇ 10 6 PBL from syngeneic donors post-SBMT.
- mice were divided into 3 experimental groups: the first group (6 mice) received intravenously a mixture of allogeneic C57 spleen and lymph node cells (20 ⁇ 10 6 cells) for induction of allo-CMI; the second group (6 mice) received identical cell therapy with additional in vivo potentiation of GVL by rhIL2 treatment (12 ⁇ 10 4 IU ⁇ 3/day for 3 days, IP); the third group (7 mice) received a mixture of syngeneic spleen and lymph node cells, with an identical in vivo rhIL2 treatment. One week later, aliquots of 10 5 cells from a pool of 2-3 spleens obtained from each experimental group were adoptively transferred to secondary BALB mice.
- mice inoculated with spleen cells from control mice given 10 3 BCL1 cells, or mice given syngeneic BALB lymphocytes with in vivo rhIL2 developed leukemia and died within 40 and 60 days, respectively.
- secondary recipients of 10 5 spleen cells obtained from mice that were treated with allo-CMI, using allogeneic C57 cells alone showed no measurable GVL effects since all recipients developed leukemia.
- addition of rhIL2 in vivo following administration of C57 spleen and lymph node cell mixtures induced substantial anti-leukemic effects and 50% of the secondary adoptive recipient mice remained leukemia-free for >125 days (FIG. 3).
- All F1 recipients were divided into two groups.
- the first group of 33 mice received no additional treatment.
- Mice in the second group 25 mice were injected with rhIL2 (12 ⁇ 10 4 IU ⁇ 2/day for 5 days, IP) in an attempt to further increase efficacy of cell therapy by continuous activation of rhIL2-dependent effector cells in vivo.
- Aliquots of 10 5 cells obtained from a pool of spleen cells prepared from mice of either experimental group were adoptively transferred to secondary BALB recipients.
- 10 of 33 secondary recipients of spleen cells obtained from the first experimental group remained disease-free for >150 days.
- This female patient was diagnosed with acute myclogenous leukemia (AML), French American British (FAB) classification M4, and was in first complete remission (i.e., no evidence of disease) at the time of autologous stem cell transplantation (ASCT). The patient was 41 years old at the time of ASCT.
- AML acute myclogenous leukemia
- FAB French American British classification M4
- ASCT autologous stem cell transplantation
- ASTA-Z Mafosfamide
- ASTA-Z was provided by Drs. M. Peukert and H. Sindermann (Astawerke, Bielefeld, Germany) as a lyophilized powder and was freshly dissolved in saline before use. Autologous cells were resuspended at a concentration of 20 ⁇ 10 6 cells/ml in Hank's medium containing 4% human serum albumin. ASTA-Z was then added to a final concentration of 100 ug/ml and the cells were incubated in the ASTA-Z at 37° C. for 30 min.
- ASCT consisted of 2.5 ⁇ 10 8 nucleated bone marrow cells/kg, infused intravenously (IV) on day 0.
- This female patient was diagnosed with AML, FAB M5, and was in first complete remission at the time of ASCT.
- the patient was 42 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, (days ⁇ 9 to ⁇ 6), as well as Cytoxan, 50 mg/kg, days ⁇ 5 to ⁇ 2, Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- the autologous bone marrow cells to be infused were purged by treatment with ASTA-Z.
- Autologous cells were resuspended at a concentration of 20 ⁇ 10 6 cells/ml in Hank's medium containing 4% human serum albumin.
- ASTA-Z was then added to a final concentration of 100 ug/ml and the cells were incubated in the ASTA-Z at 37° C. for 30 min. After this, the cells were washed twice in Hank's medium, counted and cryopreserved.
- ASCT consisted of 1 ⁇ 10 8 nucleated bone marrow cells/kg, infused IV on day 0.
- This female patient was diagnosed with AML, FAB M3, and was in first complete remission at the time of ASCT.
- the patient was 32 years old at the time of ASCT.
- a conditioning regimen of Busulfan, 4 mg/kg, (days ⁇ 9 to ⁇ 6), as well as Cytoxan, 50 mg/kg, days ⁇ 5 to ⁇ 2, Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of non-purged bone marrow cells, and 0.79 ⁇ 10 8 nucleated cells/kg were infused IV on day 0.
- the patient received PBL from an HLA-matched donor at an equivalent dose of 10 7 T cells/kg. On day +1, she also received 6 ⁇ 10 6 IU of rhIL-2/m 2 by subcutaneous injection. No GVHD was observed.
- This male patient was diagnosed with AML, FAB M2, and was in first complete remission at the time of ASCT.
- the patient was 23 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, days ⁇ 9 to ⁇ 6, Cytoxan 60 mg/kg, days ⁇ 3 to ⁇ 2, Thiotepa 5 mg/kg/day, days ⁇ 5 to ⁇ 4, Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of non-purged 1.37 ⁇ 10 8 nucleated bone marrow cells/kg, infused IV on day 0.
- the patient received PBL from an HLA-matched donor at an equivalent dose of 10 7 T cells/kg.
- he also received 6 ⁇ 10 6 IU of rhIL-2/m 2 by subcutaneous injection.
- GVHD was suspected (Grade I) in the skin.
- This male patient was diagnosed with chronic myelogenous leukemia (CML) in chronic phase.
- CML chronic myelogenous leukemia
- the original CML karyotype was positive for the Philadelphia chromosome (Ph+).
- the patient was in chronic phase (CP) and was Ph ⁇ at the time of ASCT.
- the patient was 51 years old at the time of ASCT.
- TBI total body irradiation
- ASCT consisted of non-purged 0.5 ⁇ 10 8 nucleated bone marrow cells/kg, infused IV on day 0.
- CAL cytokine-activated lymphocytes
- This female patient was diagnosed with AML, FAB M2, and was in first complete remission at the time of ASCT.
- the patient was 50 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, days ⁇ 9 to ⁇ 6, Cytoxan 60 mg/kg, days ⁇ 3 to ⁇ 2, Thiotepa 5 mg/kg/day, days ⁇ 5 to ⁇ 4, Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of non-purged 0.64 ⁇ 10 8 nucleated bone marrow cells/kg infused IV on day 0.
- WBC 4,400/mm 3 ; Hb: 9.5 g %; platelets: 66,000/mm 3
- the patient received 5 ⁇ 10 7 T cells/kg of PBL from an HLA-matched sister.
- the patient received a second dose of 6.1 ⁇ 10 7 T cells/kg of PBL from the HLA-matched sister.
- she also received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD was observed.
- This male patient was diagnosed with CML.
- the original CML karyotype was Ph+.
- the patient was in chronic phase (CP) and 50% of his marrow cells were Ph+ (i.e., the patient was Ph+) at the time of ASCT.
- the patient was 47 years old at the time of ASCT.
- Prior to ASCT he received a conditioning regimen of TBI 200 cGY/day, days ⁇ 5 to ⁇ 3, and Cytoxan 60mg/kg, days ⁇ 2 to ⁇ 1.
- ASCT consisted of non-purged 0.98 ⁇ 10 8 nucleated bone marrow cells/kg, infused IV on day 0.
- This male patient was diagnosed with non-Hodgkin's lymphoma (NHL), Burkitt-like, and was in a second partial remission at the time of ASCT.
- NDL non-Hodgkin's lymphoma
- the term “partial remission” indicates at least a 50% response (i.e., at least a 50% reduction of lymphoma cell mass) but with continued evidence of disease.
- the patient was 36 years old at the time of ASCT.
- etoposide Prior to ASCT, he received a conditioning regimen of etoposide, 200 mg/M 2 /day, days ⁇ 6 to ⁇ 3, thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2, Ara-C, 200 mg/m 2 /day, days ⁇ 4 to ⁇ 1, Cytoxan, 60 mg/kg/day, day ⁇ 3, and melphalan, 60 mg/m 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 0.74 ⁇ 10 8 /kg viable bone marrow nucleated cells plus 2.36 ⁇ 10 8 /kg viable peripheral blood stem cells.
- Subcutaneous GM-CSF 5 ug/kg/day, was administered from day +1 to day +18.
- the autologous cells Prior to ASCT, the autologous cells were purged with Dynal magnetic beads coated with anti-CD19 for elimination of residual lymphoma cells.
- This male patient was diagnosed with NHL, follicular mixed IV A, and was in a second partial remission at the time of ASCT.
- the patient was 39 years old at the time of ASCT.
- Prior to ASCT he received a conditioning regimen of etoposide, 200 mg/M 2 /day, days ⁇ 6 to ⁇ 3; thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2; Ara-C, 200 mg/m 2 /day, days ⁇ 4 to ⁇ 1; Cytoxan, 60 mg/kg/day, day ⁇ 3; and melphalan, 60 mg/m 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 0.5 ⁇ 10 8 nucleated bone marrow cells/kg, infused IV on day 0. Prior to ASCT, the autologous cells were purged with Dynal magnetic beads coated with anti-CD19 for elimination of contaminating tumor cells.
- the patient received 5 ⁇ 10 7 T cells/kg of PBL from an HLA-matched sister.
- the patient received 5 ⁇ 10 7 T cells/kg of PBL from the same donor.
- the patient also received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD was observed.
- the patient received 0.5 ⁇ 10 7 CAL/kg from the HLA-matched sister. The CAL were produced by exposing the donor's PBL to 6,000 IU/ml rhIL-2 for four days in culture. No GVHD was observed.
- This female patient was diagnosed with NHL, mixed cellularity II A, and was in a second complete remission at the time of ASCT.
- the patient was 36 years old at the time of ASCT.
- she Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m 2 /day, days ⁇ 6 to ⁇ 3, thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2, Ara-C, 200 mg/m 2 /day, days ⁇ 4 to ⁇ 1, Cytoxan, 60 mg/kg/day, day ⁇ 3, and melphalan, 60 mg/m 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 0.94 ⁇ 10 8 non-purged nucleated bone marrow cells/kg plus 3.9 ⁇ 10 7 peripheral blood stem cells mobilized by G-CSF prior to collection with the CS 3000® Plus blood cell separator (Baxter Healthcare Corporation, Fenwal System Catalogue No. 4R4538). Cells were infused IV on day 0.
- the CAL cells were produced by exposing the donor's PBL to 6,000 IU/ml rhIL-2 for four days in culture. Starting at week 23, on the same day as the administration of the Allo-CCI treatment, the patient also received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD was observed.
- This female patient was diagnosed with NHL, immunoblastic, and was in a second complete remission at the time of ASCT.
- the patient was 21 years old at the time of ASCT.
- she Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m 2 /day, days ⁇ 6 to ⁇ 3; thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2; Ara-C, 200 Mg/M2/day, days ⁇ 4 to ⁇ 1; Cytoxan, 60 mg/kg/day, day ⁇ 3; and melphalan, 60 mg/M 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 3.82 ⁇ 10 8 non-purged bone marrow cells/kg plus 1.29 ⁇ 10 8 peripheral blood stem cells mobilized with G-CSF prior to collection with the CS 3000® Plus blood cell separator. Cells were infused IV on day 0.
- the patient received 5 ⁇ 10 7 T cells/kg of PBL from an HLA-matched sister.
- the patient received a second infusion of 5 ⁇ 10 7 T cells/kg of PBL from the HLA-matched sister.
- the patient received a third infusion of 5 ⁇ 10 7 T cells/kg of PBL from the same donor. No GVHD was observed, but the patient did not accept the suggestion that she receive in vivo rhIL2.
- the patient received a fourth infusion of 5 ⁇ 10 7 T cells/kg of PBL from the HLA-matched sister.
- the patient also received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- This female patient was diagnosed with NHL, diffuse large cell, and was in a condition of relapse at the time of ASCT.
- the patient was 21 years old at the time of ASCT.
- she Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m 2 /day, days ⁇ 6 to ⁇ 3; thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2; Ara-C, 200 mg/m 2 /day, days ⁇ 4 to ⁇ 1; Cytoxan, 60 mg/kg/day, day ⁇ 3; and melphalan, 60 mg/m 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 1.8 ⁇ 10 8 non-purged mononuclear bone marrow cells/kg, infused IV on day 0.
- This male patient was diagnosed with AML, FAB M5, and was in first complete remission at the time of ASCT.
- the patient was 46 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, days ⁇ 9 to ⁇ 6; Cytoxan 60 mg/kg, days ⁇ 3 to ⁇ 2; Thiotepa 5 mg/kg/day, days ⁇ 5 to ⁇ 4; Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of 1.39 ⁇ 10 8 non-purged bone marrow cells infused IV on day 0. At week 11, the patient received 3.86 ⁇ 10 7 T cells/kg of PBL from an HLA-matched brother. No GVHD developed.
- This female patient was diagnosed with AML, FAB M3, and was in second partial remission at the time of ASCT.
- the patient was 12 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, days ⁇ 9 to ⁇ 6; Cytoxan 60 mg/kg, days ⁇ 3 to ⁇ 2; Mitoxantrone 6 mg/m 2 /day, days ⁇ 5 to ⁇ 4; Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of 1.14 ⁇ 10 8 non-purged marrow cells infused IV on day 0.
- the patient received 2 ⁇ 10 7 T cells/kg of single locus-mismatched PBL from her mother.
- the patient received 1000 mg/m 2 Cytoxan in order to improve the efficacy and temporal engraftment of a second infusion of the donor's PBL.
- the patient received 5 ⁇ 10 7 T cells/kg from the same donor.
- the patient also received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD has been noted thus far.
- This male patient was diagnosed with AML, FAB MS, and was in first complete remission at the time of ASCT.
- the patient was 61 ⁇ 2 years old at the time of ASCT.
- a conditioning regimen of Busulfan 4 mg/kg, days ⁇ 9 to ⁇ 6; Cytoxan 60 mg/kg, days ⁇ 3 to ⁇ 2; Thiotepa 5 mg/kg/day, days ⁇ 5 to ⁇ 4; Cotrimoxazol, 10 mg/kg, days ⁇ 10 to ⁇ 2, Allopurinol, 300 mg/kg, days ⁇ 10 to ⁇ 1 and Ara-C, 25 mg intrathecally.
- ASCT consisted of 2.7 ⁇ 10 8 non-purged marrow cells infused IV on day 0. At week 14, the patient received 5 ⁇ 10 7 T cells/kg of single locus-mismatched PBL from his father. No GVHD has developed, and the patient is scheduled to receive a second dose of allo-CMI plus in vivo rhIL2.
- etoposide 200 mg/m 2 /day, days ⁇ 6 to ⁇ 3; thiotepa, 40 mg/m 2 /day, days ⁇ 5 to ⁇ 2; Ara-C, 200 mg/m 2 /day, days ⁇ 4 to ⁇ 1; Cytoxan, 60 mg/kg/day, day ⁇ 3; and melphalan, 60 mg/m 2 /day, days ⁇ 2 to ⁇ 1.
- ASCT consisted of 2.15 ⁇ 10 8 non-purged G-CSF-mobilized peripheral blood stem cells, infused IV on day 0.
- the patient received 3 ⁇ 10 7 T cells/kg of PBL from an HLA-matched sister.
- the patient received a second infusion of 3 ⁇ 10 7 T cells/kg of PBL from the same donor.
- the patient also received 6 ⁇ 10 6 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- This female patient was diagnosed with metastatic breast cancer, with metastases to the liver and spine. She underwent a right partial mastectomy with axillary lymph node dissection showing involvement of 18/35 lymph nodes.
- the patient was 43 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of carboplatin, 200 mg/m 2 /day, days ⁇ 7. to ⁇ 4; thiotepa, 60 mg/m 2 /day, days ⁇ 6 to ⁇ 4; etoposide, 200 Mg/m 2 /day, days ⁇ 5 to ⁇ 3; and melphalan, 60 mg/m 2 /day, days ⁇ 4 to ⁇ 3.
- ASCT consisted of 3.7 ⁇ 10 8 peripheral blood stem cells cells/kg, infused IV on day 0.
- the stem cells were collected after mobilization with G-CSF (7.5 mg/kg/day for 5 days) using three collections with the CS 3000® Plus blood cell separator.
- G-CSF 7.5 mg/kg/day for 5 days
- a fully HLA-matched (A, B, DR and mixed lymphocyte reaction (MLR)-negative) sibling was chosen as donor of PBL for Allo-CMI.
- MLR mixed lymphocyte reaction
- the patient received 5 ⁇ 10 7 T cells/kg of PBL from the HLA-matched sibling.
- the patient also received 6 ⁇ 10 6 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- This male patient was diagnosed with metastatic breast cancer, with metastases to the bone marrow, sternum and vertebrae T 4 to T 7 . He underwent lumpectomy with axillary lymph node dissection showing involvement of 16/18 lymph nodes. The patient was 36 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of carboplatin, 200 mg/m/dlay, days ⁇ 7 to ⁇ 4; thiotepa, 60 mg/m 2 /day, days ⁇ 6 to ⁇ 4; etoposide, 200 mg/m 2 /day, days ⁇ 5 to ⁇ 3; and melphalan, 60 mg/M 2 /day, days ⁇ 4 to ⁇ 3.
- carboplatin 200 mg/m/dlay, days ⁇ 7 to ⁇ 4
- thiotepa 60 mg/m 2 /day, days ⁇ 6 to ⁇ 4
- etoposide 200 mg/m 2 /day, days ⁇ 5 to ⁇ 3
- ASCT consisted of 1.81 ⁇ 10 8 peripheral blood stem cells cells/kg, infused IV on day 0.
- the stem cells were collected after mobilization with G-CSF (7.5 mg/kg/day for 5 days) using three collections with the CS 3000® Plus blood cell separator.
- G-CSF 7.5 mg/kg/day for 5 days
- a fully HLA-matched (A, B, DR and mixed lymphocyte reaction (MLR)-negative) brother was chosen as donor of PBL for Allo-CMI.
- the patient received 2.3 ⁇ 10 7 T cells/kg of PBL from the HLA-matched brother.
- the patient aIlso received 6 ⁇ 10 6 IU of rhIL-2/m 2 /day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- PBL 2 PBL + IL2 13 1CR BU/CY + TT ABMT: Non-Purged 1.
- PBL CML 5 CP(Ph ⁇ ) CY/TBI ABMT: Non-Purged 1.
- PBL + IL2 3. CAL + IL2 7 CP(Ph + ) CY/TBI ABMT: Non-Purged 1.
- Patient No. 3 is alive and well over 34 months after ASCT.
- Patient No. 5 is alive and well over 23 months after ASCT, showing no signs of the Philadelphia chromosome (Ph-) by cytogenetic analysis and being negative by PCR for the bcr/abl translocation characteristic of the Philadelphia chromosome.
- the patient is receiving 9 ⁇ 10 6 units of IFN ⁇ (Roferon A, S.C.) every day.
- Patient No. 7 is alive and well over 21 months post-ASCT. Currently, the patient is on IFIN ⁇ treatment, and is hematologically normal with no clinical sign of disease.
- Patient No. 10 is alive and well over 15 months after ASCT with no evidence of disease.
- Patient No. 12 underwent relapse at 3 months post-ASCT and died at 5 months post-ASCT.
- Cytokines used in the following experiments were obtained as follows: (1) rhIL2 was provided by Dr. C. R. Franks (EuroCetus BY, Amsterdam, The Netherlands) as a lyophilized powder in 1 mg vials contianing 18 ⁇ 10 6 international units (IU). (2) Recombinant interferon-gamma (rIFN ⁇ ) was provided by Roussel Uclaf (Romainville, France) as a lyophilized powder containing 2 ⁇ 10 7 U/mg. (3) Recombinant human IL-6 (rIL-6) was kindly provided by Dr. M. Revel and Dr. O.
- Lymphocytes were preactivated in vitro with rhIL2 or with combinations of rhIL2 and other cytokines for four days at 37° C. Concentrations of cytokines used for in vitro incubation of lymphocytes were as follows: (a) rhIL2: 6000 IU/ml; (b) rIL6: 100-1000 U/ml; (c) rIL7: long/ml; and (d) IFNy: 1000 U/ml. Anti-tumor effects of CAL collected post-culturing were assayed against natural killer (NK)-sensitive K562 tumor cells and NK-resistant Daudi tumor cells.
- NK natural killer
Abstract
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.
Description
- This invention relates to methods of eradicating residual tumor cells following surgical intervention, chemotherapy and/or radiotherapy. The methods involve autologous bone marrow transplantation followed by administration of allogeneic peripheral blood leukocytes. More particularly, this invention relates to use of HLA-compatible allogeneic peripheral blood lymphocytes (PBL), following autologous bone marrow and/or peripheral blood stem cell transplantation, to induce a graft-versus-malignant cell response. Such a response is instrumental in prevention of disease relapse.
- Patients with malignant hematological disorders resistant to conventional doses of chemotherapy and/or radiation may be treated by autologous or allogeneic bone marrow transplantation. Bone marrow transplantation (BMT) makes it possible to administer to patients with resistant disease high, “supra-lethal,” combinations of chemotherapy and radiation, ignoring the irreversible toxicity of such therapeutic combinations on the normal bone marrow compartment. Nevertheless, such “debulking” of a patient's tumor(s) can leave a fraction of residual malignant cells that may lead to disease relapse. Several lines of evidence suggest that a significant proportion of the beneficial effect of allogeneic BMT (i.e., BMT from an individual not genetically identical to the host patient) stems from cell-mediated interactions of immune cells of donor origin against residual tumor cells in the host that have escaped the chemoradiotherapy debulking regimen.
- Following allogeneic BMT, the incidence of relapse is significantly lower in leukemia patients with clinical manifestations of acute or chronic graft versus host disease (GVHD), as compared with patients with no GVHD, indicating that immune-mediated allogeneic interactions of immunocompetent cells of donor origin against the host are also accompanied by graft vs. leukemia (GVL) effects. Weiden et al., N. Engl. J. Med. 300: 1068 (1979); Weiden et al., N. Engl. J. Med. 304: 1529-33 (1981); Weiden et al., Transplantation 13: 248-51 (1981); Barrett et al., Blood 74: 862 (1989); Sullivan et al., Blood 73: 1720 (1989); Horowitz et al., Blood 75: 555 (1990); Slavin et al., Bone Marrow Transplant. 6: 155-61 (1990).
- Higher relapse rates seem to occur in patients undergoing allogeneic BMT with T-lymphocyte depletion for prevention of GVHD, compared to recipients of non-T cell depleted marrow allografts, regardless of the severity of GVHD. Horowitz et al., Blood 75: 555 (1990); Slavin et al., Bone Marrow Transplant. 6: 155-61 (1990); Goldman et al., Ann. Inter. Med. 108: 806-14 (1988); Ringden and Horowitz, Transplant. Proc. 21: 2989-92 (1989); Goldman et al., Ann. Int. Med. 108: 806 (1988). Likewise, relapse rates in patients with acute leukemia or chronic myeloid leukemia reconstituted by bone marrow grafts obtained from an identical twin (syngeneic grafts) are significantly higher than in those reconstituted by bone marrow cells obtained from an HLA-identical but non-syngeneic sibling. Ringden and Horowitz, Transplant. Proc. 21: 2989-92 (1989). Similarly, relapse rates following transplantation of the patient's own (autologous) marrow, even following adequate purging in vitro for elimination of residual leukemia cells, are significantly higher than following allogeneic BMT. Armitage, Curr. Opinion in Hematol. 1993: 240-45 (1993). Thus, the less-than optimal results with autologous BMT (ABMT) are similar to the results seen with syngeneic marrow transplantation. All of the above data suggests that in practical terms GVHD or GVHD-potential correlates with a lower incidence of relapse.
- Allogeneic donor cells may also play a role against lymphoma, as shown in experimental animals, Slavin et al., Cancer Immunol. Immunother. 11: 155-58 (1981), and humans. Phillips et al., J. Clin. Oncol. 4: 480-88 (1986); Ernst et al., Proc. of the 4th International Conference on Lymphoma, Lugano 1990, Abstract #P35; Chopra et al., J. Clin. Oncol. 10: 1690-95 (1992). As shown in experimental animals, graft-versus-tumor effects (GVT), similar to graft-versus-leukemia effects (GVL), may occur following BMT, independently of GVHD. Moscovitch and Slavin, J. Immunol. 132: 997-1000 (1984).
- Although GVHD-associated anti-leukemia effector mechanisms may be of benefit in BMT, nevertheless GVHD represents one of the major obstacles in allogeneic- BMT, even among perfectly HLA-matched siblings. Acute GVHD develops in the majority of recipients of allogeneic BMT, with clinically significant manifestations in 26-64% of the recipients despite optimal post-transplant immunosuppressive prophylaxis. Storb et al., Blood 73: 1729 (1989). Chronic GVHD may occur in up to 45% of long term survivors. Storb et al., Blood 73: 1729 (1989). There is no satisfactory therapy for patients with established GVHD and hence patients with severe manifestations of acute or chronic forms of the disease are prone to develop multisystem complications that may require frequent hospitalizations, leading to poor quality of life and occasionally serious or even fatal complications.
- GVHD following allogeneic BMT can be prevented by adequate pretransplant T-lymphocyte depletion, using no post-transplant anti-GVHD prophylaxis. Reisner et al., In: Slavin, S (ed.),Tolerance in Bone Marrow and Organ Transplantation. Elsevier, Amsterdam (1984), p. 293; Waldmann et al., Lancet 2: 483-85 (1984); Slavin et al., Transplant. Proc. 17: 465-67 (1985). BMT without GVHD represents a better tolerated procedure that may necessitate shorter hospitalization with superior subjective immediate outcome following allogeneic BMT. In addition, the quality of life of long-term survivors without GVHD is clearly better than for those patients with severe acute or chronic GVHD.
- Unfortunately, the advantages of GVHD-free-allogeneic BMT are counterbalanced by other serious complications due to untoward effects of T-lymphocyte depletion, such as increased incidence of graft rejection, occurring in 10-30% of recipients, as well as increased rates of tumor relapse. Martin et al., Bone Marrow Transplant. 3: 445 (1988); Kernan et al., Transplantation 43: 842 (1987); Waldmann et al., Lancet 2: 483-85 (1984); Slavin et al., Transplant. Proc. 17: 465-67 (1985). Consequently, there seems to be no clear evidence to date for a significant overall benefit of GVHD prevention by T-lymphocyte depletion.
- Clearly, it would be a significant advance in the art to be able to combine the benefits of minimal or controllable GVHD risk following ABMT or ASCT with induction of graft-versus-malignant cell response that may be associated with GVHD following allogeneic BMT.
- The present invention includes a method of treating a human cancer patient who has undergone a malignant cell debulking regimen. Generally the patient is considered to be at risk for disease relapse due to a population of residual malignant cells that may remain viable in the patient following the debulking procedure. A sample of stem cells, taken from the patient, is obtained and determined to be suitable for autologous transplantation into the patient. This sample is used to perform an autologous transplant of the patient, i.e, infusing the patient's stem cells back into the patient. The patient is then monitored until the patient is partially hematopoiesis recovered but is not fully immune-reconstituted. Then, the patient is administered an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a clinically significant graft-versus-malignant cell response. The patient is then monitored for levels of malignant cells deriving from any residual malignant cells that might have been present following the original debulking procedure. This monitoring may constitute one or more molecular or cellular assays to detect or quantify malignant cells, may constitute a monitoring program to detect clinical signs of relapse, or any combination of these monitoring methods.
- As used herein, a clinically significant response permits, for example, the patient to avoid relapse, substantially prolongs the time to relapse or otherwise engenders a beneficial condition that significantly prolongs life. A graft-versus malignant cell response is not clinically significant unless there is some clinical benefit to the patient. Evidence for a clinically significant response may include, for example, absence or delay of relapse, evidence for elimination of minimal residual disease, i.e., elimination of disease-specific markers or, where appropriate, elimination of markers directed to host-specific cells.
- The regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- a) treating the patient by administration (e.g., infusion) of about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes;
- b) monitoring the patient for indications of a graft-versus-malignant cell response; and
- c) if no or insufficient graft-versus-malignant cell response develops in the patient, escalating the treatment by performing at least one of the following procedures: (1) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes greater than the number of lymphocytes administered in step (a); (2) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes at least as great as the number of lymphocytes administered in step (a), accompanied by administration of at least one T-cell-activating cytokine to said patient; (3) administration of HLA-compatible, allogeneic cytokine-activated lymphocytes (CAL) to said patient; and (4) administration of HLA-compatible, allogeneic CAL, accompanied by administration in vivo of at least one T-cell-activating cytokine to said patient. More than one of these procedures can be performed if no or insufficient graft-versus-malignant cell response develops in the patient following the first or subsequent procedure.
- In an alternative embodiment, step (a) above can be augmented by administering, concomitant with the allogeneic lymphocytes, at least one T-cell-activating cytokine to the patient. Since the T-cell-activating cytokine is administered directly to the patient, the infused allogeneic lymphocytes are exposed to the cytokine in vivo.
- The present invention also includes an alternative method of treating a human cancer patient who has undergone a malignant cell debulking regimen. Generally the patient is considered to be at risk for disease relapse due to a population of residual malignant cells that may remain viable in the patient following the debulking procedure. A sample of stem cells, taken from the patient, is obtained and determined to be suitable for autologous transplantation into the patient. This sample is used to perform an autologous transplant of the patient, i.e, infusing the patient's stem cells back into the patient. The patient is then monitored until the patient is partially hematopoiesis recovered but is not fully immune-reconstituted. Then, the patient is administered an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a mild graft-versus-host response. The patient is then monitored, as above, for levels of malignant cells deriving from any residual malignant cells that might have been present following the original debulking procedure.
- As used herein, the term “graft-versus-host response” includes but is not limited to the classic clinical symptoms of graft-versus host disease (GVHD), known to those having ordinary skill in the art. The term “graft-versus-host response” also includes molecular or cellular responses that correlate with the clinical symptoms of GVHD or with the impending onset of the clinical symptoms of GVHD.
- For the above-described alternative method, the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- a) treating the patient by administration of about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes;
- b) monitoring the patient for indications of a mild graft-versus-host response; and
- c) if no or insufficient graft-versus-host response develops in the patient, escalating the treatment by performing at least one of the following procedures: (1) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes greater than the number of lymphocytes administered in step (a); (2) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes at least as great as the number of lymphocytes administered in step (a), accompanied by administration of at least one T-cell-activating cytokine to said patient; (3) administration of HLA-compatible, allogeneic CAL to said patient; and (4) administration of HLA-compatible, allogeneic CAL, accompanied by administration in vivo of at least one T-cell-activating cytokine to said patient. More than one of these procedures can be performed if no or insufficient graft-versus-host response develops in the patient following the first or subsequent procedure.
- In an alternative embodiment, step (a) above can be augmented by administering, concomitant with the allogeneic lymphocytes, at least one T-cell-activating cytokine to the patient. Since the T-cell-activating cytokine is administered directly to the patient, the infused allogeneic lymphocytes are exposed to the cytokine in vivo.
- In an alternative embodiment, the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- a) administering to the patient about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes and at least one T-cell-activating cytokine to the patient;
- b) monitoring the patient for signs of a mild graft-versus-host response;
- c) if no or insufficient graft-versus-host response develops in the patient, administering about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic CAL and at least one T-cell-activating cytokine to the patient;
- d) monitoring the patient for signs of a mild graft-versus-host response;
- Alternatively, CAL may be given in the initial infusion. In this case the regimen for administration of an HLA-compatible leukocyte preparation including lymphocytes may comprise the following steps in sequence:
- a) administering to the patient about 105 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes in which at least some of the HLA-compatible, allogeneic peripheral blood lymphocytes are CAL, and at least one T-cell-activating cytokine to the patient;;
- b) monitoring the patient for signs of a mild graft-versus-host response;
- c) if no or insufficient graft-versus-host response develops in the patient, administering about 105 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic CAL and at least one T-cell-activating cytokine to the patient;
- d) monitoring the patient for signs of a mild graft-versus-host response;
- In any of the above described methods, the cytokine can be, without limitation, any one or more of the following: interleukin 2 (IL2), interleukin 4 (IL4), interleukin 5 (IL5), interleukin 6 (IL6), interleukin 7 (IL-7), interferon alpha (IFNα), interferon gamma (IFNγ) and tumor necrosis factor (TNFα). Any of these cytokines can be a native factor obtained from natural sources, a factor produced by recombinant DNA methodology, a chemically synthesized polypeptide or other molecule, or any derivative having the functional activity of the native factor.
- The stem cells used in the above-described methods may be obtained from bone marrow, from the peripheral circulation, or, where appropriate, from fetal sources such as fetal tissue, fetal circulation and umbilical cord blood. Cancer patients treatable with the methods of the present invention are any patients having a pathological condition caused by malignant cells, including without limitation leukemia, lymphoma, and breast cancer. The HLA-compatible allogeneic cells employed in the present invention preferably are fully HLA-matched with the patient. Alternatively the allogeneic cells may be at least haploidentical with the patient. If the allogeneic cells are derived from a sibling of the patient, the cells preferably are fully HLA matched with the patient, although some mismatch may be tolerated. For example, the allogeneic cells from a sibling to the patient may, in some cases, be single HLA locus-mismatched. If the allogeneic cells are derived from an unrelated individual, preferably the cells are fully HLA matched with the patient.
- The present invention further includes an article of manufacture comprising packaging material and a biological cell container within the packaging material. The packaging material contains a label or package insert indicating that the biological cell container, and/or any contents therein, are to be used in any of the above-described methods for treating a human cancer patient.
- FIG. 1 depicts the results of adoptive transfer of spleen cells obtained from lethally irradiated F1 mice transplanted with 107 syngeneic bone marrow cells and 105 BCL1 cells in addition to 20-30×106 PBL from allogeneic mice with (A, n=40) or without (B, n=40) concomitant in vivo rhIL2 treatment (12×104 IU×2/day for 5 days IP). A similar group received syngeneic (F1) PBL given with (C, n=20) or without (D, n=20) rhIL2. A control group had adoptive transfer of spleen cells obtained from 10 untreated F1 recipients (E, n=20).
- FIG. 2 depicts the results of adoptive transfer of spleen cells obtained from lethally irradiated F1 mice reconstituted with 107 syngeneic bone marrow cells mixed with 105 BCL1 cells. Cell-mediated immunotherapy consisted of intravenous administration of increasing numbers of C57BL/6 spleen cells: 1×106 (A, n=10); 3×106 (B, n=10); 10×106 (C, n=10) and 30×106 (D, n=10). One of three experiments is shown.
- FIG. 3 depicts results of adoptive transfer of spleen cells obtained from BALB/c mice treated with cyclophosphamide (300 mg/kg IP), inoculated 24 hours later with 103 BCL1 cells, and one day later receiving 4×106 syngeneic, ASTA-Z-treated bone marrow cells. Immunotherapy consisted of a mixture of 20×106 allogeneic C57BL/6 spleen and lymph node cells either with (A, n=6) or without (B, n=6) rhIL2 treatment in vivo (12×104 IU×3/day for 3 days IP). Recipients of a mixture of 20×106 syngeneic BALB/c spleen and lymph node cells treated with rhIL2 (C, n=7) and recipients of 103 BCL1 cells only (D, n=10) served as controls.
- FIG. 4 depicts the results of adoptive transfer of spleen cells obtained from lethally irradiated F1 mice inoculated with 105 BCL1 cells and 30×106 bone marrow cells pre-activated in vitro for 4 days with rhIL2; mice with no additional treatment (A, n=33), mice with in vivo rhIL2 treatment (12×104 IU×2/day for 5 days IP) (B, n=25); controls: recipients of 105 spleen cells obtained from untreated control mice inoculated with 105 BCL1 cells (C, n=30).
- The present inventor has employed allogeneic peripheral blood lymphocytes, alone or in combination with cytokine treatment in vivo or in vitro, for successful elimination of minimal residual disease following chemotherapy and/or radiotherapy. Appropriate treatment regimens have been circumscribed by studies in laboratory animals, and the treatment protocols have been further extended to human patients at high risk for disease relapse.
- A spontaneous, transplantable murine B-cell leukemia/lymphoma of BALB origin (BCL1) was used to investigate elimination of minimal residual disease (MRD) following bone marrow transplantation. As used herein, MRD refers to a condition wherein residual malignant cells remain viable in a patient following a primary and/or metastatic tumor “debulking” regimen. The debulking regimen may include surgical excision, chemotherapy or radiotherapy, or any combination of these approaches. Such treatment removes a significant fraction of malignant cells from the patient, but may leave a clinically significant number of residual malignant cells that put the patient at risk of relapse. The term “tumor” as used herein includes all pathological conditions involving malignant cells; this can include “solid” tumors arising in solid tissues or organs as well as “liquid” tumors such as leukemias and lymphomas deriving from malignant transformation of hematopoietic cells.
- In autologous bone marrow transplantation (ABMT) with human patients, an individual receives his or her own bone marrow cells by infusion following a tumor debulking procedure. Generally, the bone marrow cells are taken from the patient and preserved, for example by cryopreservation, prior to the debulking procedure. This permits an otherwise lethal debulking regimen to be employed, e.g., chemotherapy or radiotherapy that severely damages or destroys the patient's bone marrow. Following the debulking procedure, the patient's bone marrow is reconstituted by stem cells present in the preserved sample of bone marrow.
- Stem cells capable of reconstituting a patient's immune system can be obtained not only by direct extraction from the bone marrow, but also from the patient's peripheral circulation following mobilization of such cells from the bone marrow. This can be accomplished by treatment of the patient with granulocyte colony stimulating factor (G-CSF) or other appropriate factors that induce movement of stem cells from the bone marrow into the peripheral circulation. Following-mobilization, the stem cells can be collected from peripheral blood by any appropriate cell apheresis technique, for example through use of a commercially available blood cell collection device as exemplified by the CS 3000® Plus blood cell collection device marketed by the Fenwal Division of Baxter Healthcare Corporation. Methods for performing apheresis with the CS 3000® Plus machine are described in Willams et al., Bone Marrow Transplantation 5: 129-33 (1990) and Hillyer et al., Transfusion 33: 316-21 (1993), both publications being incorporated herein by reference. Stem cells collected from the peripheral blood are termed herein “peripheral blood stem cells” (PBSC). The term “autologous stem cell transplantation” (ASCT) is used herein to refer to any infusion into a patient of that same patient's stem cells, derived from any appropriate source (e.g., bone marrow or peripheral circulation). As such, ABMT, where the autologous infused cells are extracted directly from the bone marrow of the patient, may be considered simply one form of ASCT.
- It is possible to create an experimental regime in mice that simulates ASCT in humans. This is done through use of stem cell donors and recipients derived from a syngeneic strain of mice. In such strains, inbreeding has created a situation in which, for practical purposes, mice within the strain are genetically identical to each other. Such mice accept tissues and organs transplanted between individuals without evidence of immune rejection, in a manner analogous to acceptance of a patient's own cells following ASCT. Transplantation of bone marrow-derived stem cells between such mice is referred to herein as “syngeneic bone marrow transplantation” (SBMT) and should be considered analogous to ABMT and ASCT in humans.
- In the present experiments, mice received a lethal dose of total body irradiation (TBI) or, alternatively, a lethal dose of cyclophosphamide administered intraperitoneally. Bone marrow cells (BMC) were extracted directly from the bone marrow of syngeneic mice. In some cases, these BMC preparations were treated with mafosfamide (ASTA-Z) to simulate a “purging” procedure in which the patient's stem cells, prior to ASCT, are treated to remove or destroy at least a fraction of any contaminating malignant cells. One day after irradiation or treatment with cyclophosphamide, the mice received 107 syngeneic bone marrow cells by infusion into the lateral tail vein. To simulate MRD, 105 BCL1 tumor cells were added to the syngeneic BMC prior to SBMT.
- Following SBMT, recipient mice received either allogeneic cell-mediated immunotherapy (Allo-CMI) or allogeneic cell-mediated cytokine-activated immunotherapy (Allo-CCI). Allo-CMI involved transfer of immunocompetent allogeneic lymphocytes (i.e., lymphocytes from a mouse strain other than that of the recipient mice) at various times and at various doses, administered post-SBMT. Generally these lymphocytes represented peripheral blood lymphocytes (PBL) or mixtures of donor spleen and lymph node cells. Allo-CCI involved transfer of allogeneic lymphocytes pre-activated in vitro with recombinant human interleukin 2 (rhIL2). As used herein, the term “CAL” refers to such “cytokine-activated lymphocytes.” In some experimental protocols, the Allo-CMI or Allo-CCI regimen was accompanied by simultaneous in vivo administration of rhIL2 to the recipient mice, in order to facilitate additional activation of the infused lymphocytes in vivo.
- Failure to develop leukemia in primary recipients does not prove elimination of all BCL1 cells, since active suppression of existing tumor cells can prevent development of overt disease in these animals. This has been documented following allogeneic BMT and rhIL2 therapy. Slavin et al., Cancer Immunol. Immunother. 11: 155 (1981); Slavin et al., Nat. Immun. Cell Growth Regul. 7: 180 (1988). To establish conclusive evidence for eradication of residual malignant cells, spleen cells from the treated, or recipient, mice were adoptively transferred to secondary syngeneic recipients. If these secondary recipients failed to develop leukemia, it was judged that the original Allo-CMI- or Allo-CCI-treated mice were free of viable malignant cells, since as few as 1-10 cells have been shown to be capable of causing disease. Slavin et al., Cancer Res. 41: 4162 (1981); Cohen et al., J. Immunol. 151: 4803-10 (1993).
- The results of the SBMT experiments with mice suggested that effective immunotherapy of MRD can be achieved in vivo by cell therapy with alloreactive lymphocytes through an effect that can be further enhanced in vivo with a short course of intermediate-dose rhIL2. GVL-like effects were also induced by infusion of CAL without causing any gross impairment of the hematopoietic capacity of BMC in lethally irradiated recipients. Moreover, GVL effects induced by allogeneic lymphocytes as well as CAL could be further enhanced by concomitant condition of stabilized blood counts) is attained, as indicated by acceptable levels of, for example, white blood cells (WBC), hemoglobin (Hb) and platelets. This condition of partial hematopoiesis recovery may be achieved in a matter of weeks following ASCT in humans, well before full immune reconstitution diminishes the likelihood of successful Allo-CMI and/or Allo-CCI.
- The Allo-CMI and Allo-CCI strategies developed in mice have been adapted to human patients in a variety of protocols undertaken by the present inventor in treating cancer patients at high risk of disease relapse. Cancer patients having acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma and metastatic breast cancer have been treated with the methods of the present invention.
- Two of the earlier-treated patients with acute myelogenous leukemia were given relatively low numbers (e.g., about 104 cells/kg) of allogeneic peripheral blood lymphocytes as a first dose, in an effort to minimize the risk of serious GVHD. Thereafter, the patients were given escalating numbers of allogeneic peripheral blood lymphocytes at various time intervals to increase the chances of clinically significant graft-versus malignant cell response. Both of these early patients (patients 1 and 2 in Example 2, set out below) relapsed and died. Following this experience, it was apparent that administration of graded increments of PBL, beginning with relatively low numbers, may not be effective. It was hypothesized that the initial low dose of allogeneic PBL produced only immunization without significant GVHD or graft-versus-malignant cell response. Thus, later, higher doses rhIL2 therapy in vivo, most likely due to continuous in vivo activation of allogeneic effector cells against residual host malignant cells.
- The data further indicate that eradication of BCL1 can be accomplished before overt clinical manifestations of GVHD in the primary recipients would have occurred, since experiments showed that GVL-like effects against BCL1 cells were achieved within 1-2 weeks following administration of allogeneic lymphocytes. This implies that temporary engraftment of allogeneic effector cells may be sufficient to induce beneficial GVL effects against MRD, without the need for permanent residence of allogeneic effector cells, which may put the patient at risk for severe GVHD across major histocompatibility barriers. Moreover, as the time interval between ASCT and the Allo-CMI/CCI treatment increases, larger numbers of donor's PBL can be administered with less likelihood of severe GVHD. Slavin et al., J. Exp. Med. 147: 963 (1978); Slavin et al., Blood 80: 535a (1992).
- As such, it is useful to administer an Allo-CMI or Allo-CCI regimen after the patient is partially hematopoiesis recovered following the original tumor debulking procedure/ASCT. This raises the likelihood that the allogeneic inoculum will be rejected by reconstituting host immune cells in due time. On the other hand, it is also desirable to undertake the Allo-CMI/Allo-CCI regimen prior to full immune reconstitution of the patient, since the likelihood of premature rejection of the allogeneic inoculum, prior to beneficial GVL/GVT effects, is thereby reduced. Since full immune reconstitution following ASCT in humans frequently requires up to one year, the patient can be monitored until a stable clinical condition (e.g., of allogeneic PBL, which otherwise might be effective, are promptly rejected by the patient and rendered ineffectual for graft-versus-malignant cell activity. Therefore, in subsequent cases, more cells (e.g., at least about 107 cells/kg) were administered in the initial dose. With this initial higher dose of allogeneic cells following ASCT, satisfactory results have been obtained in many patients within the treatment population to date.
- Allogeneic cells preferably are chosen from human leukocyte antigen (HLA)-compatible donors. Generally, HLA-compatible lymphocytes may be taken from a fully HLA-matched relative such as a parent, brother or sister. However, as shown with patient No. 12 in Example 2, below, donor lymphocytes may be sufficiently HLA-compatible with the recipient to obtain the desired result even if a sibling donor is single-locus mismatched. If a donor is unrelated to the recipient, preferably the donor lymphocytes are fully HLA matched with the recipient.
- In a preferred embodiment of the present invention, an initial dose of at least about 107 HLA-compatible allogeneic lymphocytes/kg is given once the patient has achieved a clinically stable condition (e.g., stabilized blood counts). Preferably, the patient is also administered cytokine in vivo concomitant with administration of the HLA-compatible lymphocytes,. Preferably the cytokine is rhIL2 at a dose of about 6×106 IU of rhIL2/m2/day, by subcutaneous injection, beginning on the same day as infusion of the allogeneic lymphocytes. Other appropriate cytokines may be used alone or in combination with rhIL2, as long as the desired enhancing effect is obtained. Such additional cytokines include, without limitation, native or recombinant forms of IL6, IL7 and alpha and gamma-interferon (INFα, INFγ, respectively).
- If GVHD fails to develop in a patient given these numbers of HLA-compatible allogeneic lymphocytes with concomitant in vivo cytokine, then the treatment regimen is escalated. Preferably this is done by administering a second dose of allogeneic HLA-compatible lymphocytes preactivated in vitro with cytokine. Preferably the cytokine is rhIL2, although other appropriate cytokines may be used alone or in combination with rhIL2, as long as the desired activation in vitro is obtained. Such additional cytokines include, without limitation, native or recombinant forms of IL6, IL7 and alpha-interferon (INFα), alone or in combination with IL2.
- Prior to administration of the second dose of cells comprising CAL, and contingent on the particular status of an individual patient, cyclophosphamide (Cytoxan) or other appropriate immunosuppressants may be administered to the patient to avoid rejection of the second dose of cells. That is, the immunosuppressant is given in a dose effective for killing host T cells that might otherwise operate to reject the second allogeneic inoculum; the immunosuppressant may have the added benefit of eliminating potential host suppressor cell functions that can interfere with the GVT effects of the infused CAL. Preferably, in vivo cytokine is administered to the patient concomitant with the second dose of cells (CAL).
- Although the above-described preferred embodiment is presently recommended, it is to be understood that any combination of allogeneic peripheral blood lymphocytes, in vivo cytokine and/or CAL is covered by the present invention, so long as the initial dose of cells is capable of eliciting a beneficial GVT response. This dose of cells corresponds to a number of HLA-compatible allogeneic peripheral blood lymphocytes that elicits a host response beyond mere immunization to a second dose of cells from the same or similar donor. Generally, this number corresponds to at least about 107 allogeneic peripheral blood lymphocytes/kg. However, it is possible that a lower dose of cells, e.g., about 105 cells/kg, could be used if, for example, CAL were used for the initial infusion.
- Between the Allo-CMI/CCI treatments or at the conclusion of an Allo-CMI/CCI regimen, the patient may be monitored for levels of malignant cells, i.e., for evidence of minimal residual disease. Such monitoring may comprise patient follow-up for clinical signs of relapse. The monitoring may also include, where appropriate, various molecular or cellular assays to detect or quantify any residual malignant cells. For example, in cases of sex-mismatched donors and recipients, residual host-derived cells may be detected through use of appropriate sex markers such as Y chromosome-specific nucleic acid primers or probes. In cases of single HLA locus mismatches between donors and recipients, residual host cells may be documented by polymerase chain reaction (PCR) analysis of Class I or Class II loci that differ between the donor and recipient. Alternatively, appropriate molecular markers specific for tumor cells can be employed. For example, nucleic acid primers and/or probes specific for the bcr/abl translocation in chronic myelogenous leukemia, for other oncogenes active in various tumors, for inactivated tumor suppressor genes, other tumor-specific genes, or any other assay reagents known to be specific for tumor cells, may be employed. Any of these or functionally comparable procedures may be used to monitor the patient for evidence of residual malignant cells.
- Under normal circumstances, recipients of autologous or allogeneic bone marrow grafts receive only irradiated blood products when such products are required by the patient. These products are irradiated in order to avoid the possibility of engraftment of immunocompetent T-lymphocytes derived from the donor's blood product (e.g., platelets or red blood cells). In most institutions, irradiated blood products are also used for patients receiving high dose conventional chemotherapy without transplant, e.g., blood products given following induction of remission in leukemia and lymphoma patients. Obviously, the chances for engraftment of immunocompetent T-lymphocytes from otherwise mismatched blood products is relatively small under normal circumstances. However, if immunosuppression is sufficient to permit engraftment, GVHD can be “stormy” and lethal.
- In the methods of the present invention, non-irradiated donor-type lymphocytes are used intentionally for induction of graft-versus-malignant cell effects. The methods are structured to produce transient engraftment, so as to induce graft-versus-malignant cell effects that may be accompanied by mild GVHD. Since the donor cells used in the Allo-CMI and Allo-CCI procedures are HLA-compatible with the recipient, chances of engraftment are better than if the donor's cells were not functionally matched with the patient's major histocompatibility complex. Moreover, the chance of immediate rejection on the one hand and lethal GVHD on the other hand are relatively small because of the HLA compatibility. As such, the Allo-CMI/CCI protocols of the present invention provide the possibility for transient engraftment of donor's PBL with effective GVT and with a minimal chance for induction of severe GVHD.
- The invention will be further understood with reference to the following illustrative embodiments, which are purely exemplary, and should not be taken as limiting the true scope of the present invention as described in the claims.
- I. Methods
- A. Mice.
- BALB/c (BALB), and C57BL/6 (C57), (BALB/c x C57BL/6)F1 (F1) mice, 2-6 months old, were purchased from the breeding colony of the Hebrew University-Hadassah Medical School, Jerusalem. Mice were kept under standard conditions, with acidic water (pH 2.7) and no special protective measures. Mice were given 0.5% neomycin sulfate in their drinking water for 2 weeks post-transplantation.
- B. Murine B-Cell Leukemia (BCL1).
- BCL1, a spontaneous, transplantable B-cell leukemia/lymphoma of BALB origin is characterized by marked (up to 50 fold) splenomegaly, accompanied by extreme peripheral blood lymphocytosis (>200,00/mm3) and results in death of all mice inoculated with >10-100 tumor cells. Slavin et al., Nature 272: 624 (1978); Slavin et al., Cancer Res. 41: 4162 (1981). BCLI was maintained in vivo in BALB mice by IV passage of 106-107 peripheral blood lymphocytes (PBL) obtained from tumor bearing mice. Mice with marked lymphocytosis in the blood were subsequently used as BCL1 cell donors for experimental mice. PBL counts for all experimental groups were carried out weekly. Leukemia was defined as PBL counts exceeding 20,000/mm3. At the peak of disease PBL counts usually reached >100,000/mm3.
- C. Mafosfamide (ASTA-Z).
- ASTA-Z was kindly provided by Drs M. Peukert and H. Sindermann (Astawerke, Bielefeld, Germany) as a lyophilized powder and was freshly dissolved in saline before use. ASTA-Z has been employed in vitro to reduce or eliminate malignant cell populations from bone marrow preparations. Douay et al., CR Acad. Sci. Paris t. 301, Ser III, no. 6:303 (1985).
- D. Conditioning with Radiation and Cyclophosphamide Prior to BMT.
- Mice were exposed to a single dose of 750 cGy total body irradiation (TBI) from a Philips X-ray unit (250 kV 20 mA) with a focus to skin distance of 70 cm at a dose rate of 60 cGy/min. Alternatively, mice were conditioned with freshly dissolved cyclophosphamide (CY) (300 mg/kg) (Taro, Israel) given intraperitoneally (IP). Twenty-four hours later, mice received 107 syngeneic marrow cells via the lateral tail vein.
- E. Preparation of Bone Marrow Cells (BMC).
- BMC were obtained from the femura, tibiae and humera of syngeneic mice. Mononuclear cells containing 107 BMC in 0.25 ml Hank's medium were injected into the lateral tail vein of recipients 24 hours post-radiation.
- F. Purging Procedure.
- Cells were resuspended at a concentration of 20×106 cells/ml in Hank's medium containing 4% human serum albumin. ASTA-Z was then added to a final concentration of 100 μg/ml. Both untreated control cells and ASTA-Z treated BMC were incubated at 37° C. for 30 minutes, washed twice in Hank's medium and counted. Purged or unpurged BMC (4×106) were injected into BALB mice conditioned with CY.
- G. Recombinant Human Interleukin-2 (rhIL2).
- rhIL2 provided as 1 mg Proleukin (3×106 Cetus Units, equivalent to 18×106 International Units) was kindly supplied by Dr. S. L. Aukerman, Cetus/Chiron, Calif., USA. rhIL2 was initially diluted with water for injection and subsequently rediluted with dextrose 5%. International units (IU) are used throughout the remainder of the present application.
- H. Activation of BMC by rhlL2.
- BMC were cultured in 225 cm3 flasks (Corning 25160-225, Corning Glass, Corning N.Y.) in RPMI 1640 medium (Beit Haemek, Israel) containing L-glutamine, non-essential amino acids, pyruvate, 10% bovine calf serum (BCS) and rhIL2 (6,000 IU/ml) for 4 days in a humidified incubator with 5% CO2 at 37° C. Following harvesting, viability was determined by the trypan blue exclusion method.
- I. Simulation of Minimal Residual Disease Following Syngeneic Bone Marrow Transplantation.
- In order to simulate minimal residual disease (MRD) quantitatively, 105 BCL1 cells were added to the marrow inoculum during syngeneic bone marrow transplantation (SBMT), prior to immunotherapy.
- J. Immunotherapy by Immunocompetent Allogeneic Lymphocytes.
- Allogeneic cell-mediated immunotherapy (Allo-CMI) consisted of adoptive transfer of immunocompetent allogeneic lymphocytes (PBL or a mixture of donor spleen and lymph node cells) as detailed in the results for each experiment, below. Allogeneic cell-mediated cytokine-activated immunotherapy (Allo-CCI) consisted of adoptive transfer of allogeneic lymphocytes pre-activated in vitro with rhIL2 (allogeneic “CAL”) In some experiments allogeneic lymphocyte infusion was followed by subsequent in vivo activation with rhIL2, by additional Allo-CMI with in vivo rhIL-2, or by additional Allo-CCI with in vivo rhIL-2, respectively.
- K. Detection of Residual Clonogenic BCL1 by Adoptive Transfer Experiments.
- In order to determine whether or not residual BCLI cells were present after various treatments, 105 spleen cells obtained from treated mice were adoptively transferred to untreated secondary syngeneic (BALB) recipients. Absence of leukemia (>100 days) in secondary recipients was indicative of elimination of BCL1 since as few as 1-10 cells were previously shown to cause disease.
- L. Statistical Analysis.
- The significance of differences between treated and untreated mice was calculated by the independent statistical t-test.
- II. Results
- A. Induction of Allo-CMI and Allo-CCI Effects.
- F1 mice were lethally irradiated (750 cGy) and transplanted with 107 syngeneic BMC. Following inoculation of 105 BCL1 cells to simulate MRD, varying numbers of C57 PBL were administered intravenously to induce GVL-like effects through allo-CMI. In order to detect the efficacy of allo-CMI in eradicating residual BCL1 cells, aliquots of 105 spleen cells pooled from 2-3 experimental mice were adoptively transferred to secondary normal BALB recipients, one or two weeks post-SBMT.
- FIG. 1 summarizes results obtained from three different experiments in a total of 120 mice. Injection of 20-30×106 PBL, obtained from C57 mice to induce allo-CMI after SBMT in F1 recipients, effectively eliminated residual BCL1 cells, as none of 40 secondary adoptive BALB recipients developed leukemia (>180 days). In contrast, leukemia developed in all 20 secondary BALB recipients inoculated with 105 spleen cells obtained from Fl recipients that had received 20-30×106 PBL from syngeneic donors post-SBMT. Addition of rhIL2 (12×104 IU×2/day for 5 days IP) post-transplant did not improve the disease-free survival of secondary recipients of 105 spleen cells (obtained from similarly treated F1 mice) since all 20 secondary recipient BALB mice developed leukemia (FIG. 1). Addition of rhIL2 in vivo at the same dose to recipients of 20×106 allogeneic PBL for further in vivo activation of effector cells did not induce measurable additional GVL effects since all 40 secondary BALB recipients remained disease free (>180 days) (FIG. 1).
- B. Quantitative Effect of the Number of Effector Cells on the Efficacy of Allo-CMI.
- Anti-leukemic effects mediated by allo-CMI were cell-dose dependent. As shown in FIG. 2, all SBMT recipients injected with 30×106 C57 spleen cells completely resisted the development of leukemia following inoculation of 105 BCL1 cells. Injection of 10×106 allogeneic spleen cells together with 105 BCL1 cells induced effective allo-CMI in 70% of the secondary adoptive recipients. However, reduction of allo-CMI inducing C57 spleen cells to 3×106 or 1×106 failed to eliminate residual BCL1 cells and all secondary adoptive recipients developed leukemia (FIG. 2).
- C. Induction of Allo-CMI and Allo-CMI/IL-2 Effects Following Transplantation with ASTA-Z-Purged BMC.
- The feasibility of induction of allo-CMI was investigated by conditioning with high-dose CY followed by rescue of recipients with ASTA-Z-purged syngencic BMC. BALB recipients received high-dose CY (300 mg/kg IP) and were injected 24 hours later with 103 BCL1 cells to simulate MRD. One day later, all mice received intravenously 4×106ASTA-Z treated syngeneic BMC. Mice were divided into 3 experimental groups: the first group (6 mice) received intravenously a mixture of allogeneic C57 spleen and lymph node cells (20×106 cells) for induction of allo-CMI; the second group (6 mice) received identical cell therapy with additional in vivo potentiation of GVL by rhIL2 treatment (12×104 IU×3/day for 3 days, IP); the third group (7 mice) received a mixture of syngeneic spleen and lymph node cells, with an identical in vivo rhIL2 treatment. One week later, aliquots of 105 cells from a pool of 2-3 spleens obtained from each experimental group were adoptively transferred to secondary BALB mice.
- As shown in FIG. 3, all mice inoculated with spleen cells from control mice given 103 BCL1 cells, or mice given syngeneic BALB lymphocytes with in vivo rhIL2, developed leukemia and died within 40 and 60 days, respectively. Likewise, secondary recipients of 105 spleen cells obtained from mice that were treated with allo-CMI, using allogeneic C57 cells alone, showed no measurable GVL effects since all recipients developed leukemia. In contrast, addition of rhIL2 in vivo following administration of C57 spleen and lymph node cell mixtures induced substantial anti-leukemic effects and 50% of the secondary adoptive recipient mice remained leukemia-free for >125 days (FIG. 3).
- D. Enhancement of Immunotherapeutic Effect by in vitro Activation of Allogeneic lymphocytes with rhIL2.
- The following experiment was designed to test for potential enhancements in efficacy of treatment by in vitro pre-activation of allogeneic effector cells with rhIL2. Lethally irradiated (750 cGy TBI) F1 mice were infused with 30×106 C57 BMC pre-activated in vitro for 4 days with rhIL2. BMC were mixed with 105 BCL1 cells to simulate MRD. Results of 3 separate sets of experiments gave similar results and therefore the data were pooled (FIG. 4).
- All F1 recipients were divided into two groups. The first group of 33 mice received no additional treatment. Mice in the second group (25 mice) were injected with rhIL2 (12×104 IU×2/day for 5 days, IP) in an attempt to further increase efficacy of cell therapy by continuous activation of rhIL2-dependent effector cells in vivo. Aliquots of 105 cells obtained from a pool of spleen cells prepared from mice of either experimental group were adoptively transferred to secondary BALB recipients. As shown in FIG. 4, 10 of 33 secondary recipients of spleen cells obtained from the first experimental group remained disease-free for >150 days. Additional in vivo rhIL2 therapy in the second experimental group further improved the Allo-CCI effects, as 19 of 25 secondary recipients remained disease-free for an observation period >150 days (p=0.05) (FIG. 4).
- I. Patient Treatment Protocols
- Patient No. 1.
- This female patient was diagnosed with acute myclogenous leukemia (AML), French American British (FAB) classification M4, and was in first complete remission (i.e., no evidence of disease) at the time of autologous stem cell transplantation (ASCT). The patient was 41 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of Busulfan, 4 mg/kg, days 6 through 9 pre-ASCT (days −9 to −6), as well as Cytoxan (cyclophosphamide), 50 mg/kg, days −5 to −2, Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and cytosine arabinoside (Ara-C), 25 mg intrathecally.
- Prior to ASCT, the autologous cells to be infused were purged by treatment with Mafosfamide (ASTA-Z). ASTA-Z was provided by Drs. M. Peukert and H. Sindermann (Astawerke, Bielefeld, Germany) as a lyophilized powder and was freshly dissolved in saline before use. Autologous cells were resuspended at a concentration of 20×106 cells/ml in Hank's medium containing 4% human serum albumin. ASTA-Z was then added to a final concentration of 100 ug/ml and the cells were incubated in the ASTA-Z at 37° C. for 30 min. After this, the cells were washed twice in Hank's medium and counted. Cells were cryopreserved and kept in liquid nitrogen until used. ASCT consisted of 2.5×108 nucleated bone marrow cells/kg, infused intravenously (IV) on
day 0. - On day 1 following ASCT (day +1), the patient received 104 T cells/kg of peripheral blood lymphocytes (PBL) from an HLA-matched donor. On days +3, +22, +29 and +36 she received PBL from the same donor at an equivalent dose of 105, 105, 106, and 106 T cells/kg, respectively. On day +47 she received PBL from the same donor at an equivalent dose of 107 T cells/kg. The patient showed no evidence of GVHD.
- Patient No. 2.
- This female patient was diagnosed with AML, FAB M5, and was in first complete remission at the time of ASCT. The patient was 42 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of Busulfan, 4 mg/kg, (days −9 to −6), as well as Cytoxan, 50 mg/kg, days −5 to −2, Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally.
- Prior to ASCT, the autologous bone marrow cells to be infused were purged by treatment with ASTA-Z. Autologous cells were resuspended at a concentration of 20×106 cells/ml in Hank's medium containing 4% human serum albumin. ASTA-Z was then added to a final concentration of 100 ug/ml and the cells were incubated in the ASTA-Z at 37° C. for 30 min. After this, the cells were washed twice in Hank's medium, counted and cryopreserved. ASCT consisted of 1×108 nucleated bone marrow cells/kg, infused IV on
day 0. - On day +1, the patient received 104 T cells/kg of PBL from an HLA-matched donor. On days +8, +18 and +26 she received PBL from the same donor at an equivalent dose of 105, 106, and 107 T cells/kg, respectively. On day +80 she received PBL from the same donor at an equivalent dose of 107 T cells/kg, with 3×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection beginning on day +80. The patient showed no evidence of GVHD.
- Patient No. 3.
- This female patient was diagnosed with AML, FAB M3, and was in first complete remission at the time of ASCT. The patient was 32 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of Busulfan, 4 mg/kg, (days −9 to −6), as well as Cytoxan, 50 mg/kg, days −5 to −2, Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of non-purged bone marrow cells, and 0.79×108 nucleated cells/kg were infused IV on
day 0. On day +1, the patient received PBL from an HLA-matched donor at an equivalent dose of 107 T cells/kg. On day +1, she also received 6×106 IU of rhIL-2/m2 by subcutaneous injection. No GVHD was observed. - Patient No. 4.
- This male patient was diagnosed with AML, FAB M2, and was in first complete remission at the time of ASCT. The patient was 23 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of Busulfan 4 mg/kg, days −9 to −6,
Cytoxan 60 mg/kg, days −3 to −2, Thiotepa 5 mg/kg/day, days −5 to −4, Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of non-purged 1.37×108 nucleated bone marrow cells/kg, infused IV onday 0. On day +1, the patient received PBL from an HLA-matched donor at an equivalent dose of 107 T cells/kg. On day +1, he also received 6×106 IU of rhIL-2/m2 by subcutaneous injection. GVHD was suspected (Grade I) in the skin. - Patient No. 5.
- This male patient was diagnosed with chronic myelogenous leukemia (CML) in chronic phase. The original CML karyotype was positive for the Philadelphia chromosome (Ph+). The patient was in chronic phase (CP) and was Ph− at the time of ASCT. The patient was 51 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of total body irradiation (TBI) 200 cGY/day, days −5 to −3, and Cytoxan 60mg/kg, days −2 to −1. ASCT consisted of non-purged 0.5×108 nucleated bone marrow cells/kg, infused IV on
day 0. - On day +71, as soon as blood counts had stabilized (WBC: 4,200/mm3; Hb: 11.5 g %; platelets: 133,000/mm3), the patient received 3×107 T cells/kg of PBL from an HLA-matched brother. No GVHD was observed; hence, the allo-CMI regimen was escalated. On day +107, the patient received 4.6×107 T cells/kg of PBL from the same donor. Starting on day +107, he also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. On day +240, after the Ph+ karyotype had reappeared, the patient received 4.95×107 cells/kg of cytokine-activated lymphocytes (“CAL”) from the same donor. Starting on day +240, he also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. The CAL were produced by exposing the donor's PBL to 6,000 IU/ml rhIL-2 for four days in culture.
- Patient No. 6.
- This female patient was diagnosed with AML, FAB M2, and was in first complete remission at the time of ASCT. The patient was 50 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of Busulfan 4 mg/kg, days −9 to −6,
Cytoxan 60 mg/kg, days −3 to −2, Thiotepa 5 mg/kg/day, days −5 to −4, Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of non-purged 0.64×108 nucleated bone marrow cells/kg infused IV onday 0. On day +58, as soon as blood counts had stabilized (WBC: 4,400/mm3; Hb: 9.5 g %; platelets: 66,000/mm3), the patient received 5×107 T cells/kg of PBL from an HLA-matched sister. On day +86 the patient received a second dose of 6.1×107 T cells/kg of PBL from the HLA-matched sister. Starting on day +86, she also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. - Patient No. 7.
- This male patient was diagnosed with CML. The original CML karyotype was Ph+. The patient was in chronic phase (CP) and 50% of his marrow cells were Ph+ (i.e., the patient was Ph+) at the time of ASCT. The patient was 47 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of
TBI 200 cGY/day, days −5 to −3, and Cytoxan 60mg/kg, days −2 to −1. ASCT consisted of non-purged 0.98×108 nucleated bone marrow cells/kg, infused IV onday 0. On day +55, as soon as blood counts had stabilized (WBC: 6,900/mm3; Hb: 12.0 g %; platelets: 248,000/mm3), the patient received 4×107 T cells/kg of PBL from an HLA-matched sister. No GVHD developed. On day +77, the patient received 2.8×107 cells/kg of PBL from the HLA-matched sister. Starting on day +77, he also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. - Patient No. 8.
- This male patient was diagnosed with non-Hodgkin's lymphoma (NHL), Burkitt-like, and was in a second partial remission at the time of ASCT. As used herein, the term “partial remission” indicates at least a 50% response (i.e., at least a 50% reduction of lymphoma cell mass) but with continued evidence of disease. The patient was 36 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of etoposide, 200 mg/M2/day, days −6 to −3, thiotepa, 40 mg/m2/day, days −5 to −2, Ara-C, 200 mg/m2/day, days −4 to −1, Cytoxan, 60 mg/kg/day, day −3, and melphalan, 60 mg/m2/day, days −2 to −1.
- ASCT consisted of 0.74×108/kg viable bone marrow nucleated cells plus 2.36×108/kg viable peripheral blood stem cells. Subcutaneous GM-CSF, 5 ug/kg/day, was administered from day +1 to day +18. Prior to ASCT, the autologous cells were purged with Dynal magnetic beads coated with anti-CD19 for elimination of residual lymphoma cells.
- On day +90, the patient received 5×107 cells/kg of PBL from an HLA-matched brother. The patient showed no signs of GVHD following this first cell infusion. Polymerase chain reaction (PCR) analysis using two VNTR loci (VNTR Variable Number of Tandem Repeats) revealed no evidence of circulating donor-specific cells. On day +124, the patient received 5×107 cells/kg of PBL from the same donor. This was followed by three days outpatient treatment with 6×106 IU of rhIL-2/m2/day, by subcutaneous injection, beginning on day +124.
- Fifty days later (day +174) the patient developed pancytopenia, and bone marrow biopsy revealed severe hypocellular marrow with increased numbers of large granular lymphocytes and plasma cells. Lymphocytes with a similar morphology were found in the blood. Repeated PCR using two different VNTR loci showed partial engraftment of donor cells on day +191 and 100% engraftment of donor cells on day +211. An allogeneic BMT was then performed by infusing the patient with 3.4×108/kg of the donor's marrow cells; no post-transplant anti-GVHD prophylaxis was administered. The patient had rapid three-lineage engraftment with normal platelet counts after 14 days and normal hemoglobin after 26 days. WBC normalized after 10 days with 70% neutrophils, 5% monocytes and 25% lymphocytes. Large granular lymphocytes disappeared from the blood. On day 14 following allogeneic BMT, the patient showed minimal signs of acute GVHD with involvement of skin and oral cavity. There was no intestinal or liver involvement. Since then the patient has continued to experience grade I/II mucocutaneous GVHD, partially controlled with steroids and cyclosporin A.
- Patient No. 9.
- This male patient was diagnosed with NHL, follicular mixed IV A, and was in a second partial remission at the time of ASCT. The patient was 39 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of etoposide, 200 mg/M2/day, days −6 to −3; thiotepa, 40 mg/m2/day, days −5 to −2; Ara-C, 200 mg/m2/day, days −4 to −1; Cytoxan, 60 mg/kg/day, day −3; and melphalan, 60 mg/m2/day, days −2 to −1.
- ASCT consisted of 0.5×108 nucleated bone marrow cells/kg, infused IV on
day 0. Prior to ASCT, the autologous cells were purged with Dynal magnetic beads coated with anti-CD19 for elimination of contaminating tumor cells. - At week 8 post-ASCT, the patient received 5×107 T cells/kg of PBL from an HLA-matched sister. At week 12 post-ASCT, the patient received 5×107 T cells/kg of PBL from the same donor. Starting at week 12, on the same day as the administration of the second Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. At week 16 post-ASCT, the patient received 0.5×107 CAL/kg from the HLA-matched sister. The CAL were produced by exposing the donor's PBL to 6,000 IU/ml rhIL-2 for four days in culture. No GVHD was observed.
- Patient No. 10.
- This female patient was diagnosed with NHL, mixed cellularity II A, and was in a second complete remission at the time of ASCT. The patient was 36 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m2/day, days −6 to −3, thiotepa, 40 mg/m2/day, days −5 to −2, Ara-C, 200 mg/m2/day, days −4 to −1, Cytoxan, 60 mg/kg/day, day −3, and melphalan, 60 mg/m2/day, days −2 to −1.
- ASCT consisted of 0.94×108 non-purged nucleated bone marrow cells/kg plus 3.9×107 peripheral blood stem cells mobilized by G-CSF prior to collection with the CS 3000® Plus blood cell separator (Baxter Healthcare Corporation, Fenwal System Catalogue No. 4R4538). Cells were infused IV on
day 0. - At
week 10 post-ASCT, as soon as blood counts had stabilized (WBC: 4,300/mm3; Hb: 11.2 g %; platelets: 116,000/mm3), the patient received 3×107 T cells/kg of PBL from an HLA-matched brother. At week 15 post-ASCT, the patient received 4.1×107 T cells/kg of PBL from the same donor. Starting at week 15, on the same day as the administration of the second Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. At week 23 post-ASCT, the patient received 5×107 CAL/kg from the HLA-matched brother. The CAL cells were produced by exposing the donor's PBL to 6,000 IU/ml rhIL-2 for four days in culture. Starting at week 23, on the same day as the administration of the Allo-CCI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. - Patient No. 11.
- This female patient was diagnosed with NHL, immunoblastic, and was in a second complete remission at the time of ASCT. The patient was 21 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m2/day, days −6 to −3; thiotepa, 40 mg/m2/day, days −5 to −2; Ara-C, 200 Mg/M2/day, days −4 to −1; Cytoxan, 60 mg/kg/day, day −3; and melphalan, 60 mg/M2/day, days −2 to −1.
- ASCT consisted of 3.82×108 non-purged bone marrow cells/kg plus 1.29×108 peripheral blood stem cells mobilized with G-CSF prior to collection with the CS 3000® Plus blood cell separator. Cells were infused IV on
day 0. - At
week 10 post-ASCT, the patient received 5×107 T cells/kg of PBL from an HLA-matched sister. At week 15 post-ASCT, the patient received a second infusion of 5×107 T cells/kg of PBL from the HLA-matched sister. At week 19 post-ASCT, the patient received a third infusion of 5×107 T cells/kg of PBL from the same donor. No GVHD was observed, but the patient did not accept the suggestion that she receive in vivo rhIL2. Atweek 30 post-ASCT, the patient received a fourth infusion of 5×107 T cells/kg of PBL from the HLA-matched sister. Starting at week 23, on the same day as the administration of the fourth Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date. - Patient No. 12.
- This female patient was diagnosed with NHL, diffuse large cell, and was in a condition of relapse at the time of ASCT. The patient was 21 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of etoposide, 200 mg/m2/day, days −6 to −3; thiotepa, 40 mg/m2/day, days −5 to −2; Ara-C, 200 mg/m2/day, days −4 to −1; Cytoxan, 60 mg/kg/day, day −3; and melphalan, 60 mg/m2/day, days −2 to −1.
- ASCT consisted of 1.8×108 non-purged mononuclear bone marrow cells/kg, infused IV on
day 0. - At week 6 post-ASCT, as soon as blood counts had stabilized (WBC: 4,400/mm3; Hb: 11.7 g %; platelets: 150,000/mm3), the patient received 5×107 T cells/kg of PBL from a single locus-mismatched sister. At
week 10 post-ASCT, the patient received a second infusion of 5×107 T cells/kg of PBL from the same donor. Starting atweek 10, on the same day as the administration of the second Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD was observed. - Patient No. 13.
- This male patient was diagnosed with AML, FAB M5, and was in first complete remission at the time of ASCT. The patient was 46 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of Busulfan 4 mg/kg, days −9 to −6;
Cytoxan 60 mg/kg, days −3 to −2; Thiotepa 5 mg/kg/day, days −5 to −4; Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of 1.39×108 non-purged bone marrow cells infused IV onday 0. At week 11, the patient received 3.86×107 T cells/kg of PBL from an HLA-matched brother. No GVHD developed. - Patient No. 14.
- This female patient was diagnosed with AML, FAB M3, and was in second partial remission at the time of ASCT. The patient was 12 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of Busulfan 4 mg/kg, days −9 to −6;
Cytoxan 60 mg/kg, days −3 to −2; Mitoxantrone 6 mg/m2/day, days −5 to −4; Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of 1.14×108 non-purged marrow cells infused IV onday 0. At week 16, the patient received 2×107 T cells/kg of single locus-mismatched PBL from her mother. Atweek 20, the patient received 1000 mg/m2 Cytoxan in order to improve the efficacy and temporal engraftment of a second infusion of the donor's PBL. Twenty four hours later, the patient received 5×107 T cells/kg from the same donor. Starting on the same day as the administration of the second Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been noted thus far. - Patient No. 15.
- This male patient was diagnosed with AML, FAB MS, and was in first complete remission at the time of ASCT. The patient was 6½ years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of Busulfan 4 mg/kg, days −9 to −6;
Cytoxan 60 mg/kg, days −3 to −2; Thiotepa 5 mg/kg/day, days −5 to −4; Cotrimoxazol, 10 mg/kg, days −10 to −2, Allopurinol, 300 mg/kg, days −10 to −1 and Ara-C, 25 mg intrathecally. ASCT consisted of 2.7×108 non-purged marrow cells infused IV onday 0. At week 14, the patient received 5×107 T cells/kg of single locus-mismatched PBL from his father. No GVHD has developed, and the patient is scheduled to receive a second dose of allo-CMI plus in vivo rhIL2. - Patient No.16.
- This male patient was diagnosed with NHL, mixed large and small cell, in the lymph nodes, in February of 1993. There was also heavy bone marrow involvement. He received chemotherapy (12 courses of MACOP-B), but relapsed in the lymph nodes and bone marrow in October of 1993. He underwent additional chemotherapy and was in a second partial remission at the time of ASCT, with recurrence in the marrow. The patient was 45 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen consisting of etoposide, 200 mg/m2/day, days −6 to −3; thiotepa, 40 mg/m2/day, days −5 to −2; Ara-C, 200 mg/m2/day, days −4 to −1; Cytoxan, 60 mg/kg/day, day −3; and melphalan, 60 mg/m2/day, days −2 to −1.
- ASCT consisted of 2.15×108 non-purged G-CSF-mobilized peripheral blood stem cells, infused IV on
day 0. - At week 7 post-ASCT, the patient received 3×107 T cells/kg of PBL from an HLA-matched sister. At week 11 post-ASCT, the patient received a second infusion of 3×107 T cells/kg of PBL from the same donor. Starting at week 11, on the same day as the administration of the second Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- Patient No. 17.
- This female patient was diagnosed with metastatic breast cancer, with metastases to the liver and spine. She underwent a right partial mastectomy with axillary lymph node dissection showing involvement of 18/35 lymph nodes. The patient was 43 years old at the time of ASCT. Prior to ASCT, she received a conditioning regimen of carboplatin, 200 mg/m2/day, days −7. to −4; thiotepa, 60 mg/m2/day, days −6 to −4; etoposide, 200 Mg/m2/day, days −5 to −3; and melphalan, 60 mg/m2/day, days −4 to −3.
- ASCT consisted of 3.7×108 peripheral blood stem cells cells/kg, infused IV on
day 0. The stem cells were collected after mobilization with G-CSF (7.5 mg/kg/day for 5 days) using three collections with the CS 3000® Plus blood cell separator. Following ASCT, the patient recovered with no complications and was discharged onday 20 post-ASCT. - A fully HLA-matched (A, B, DR and mixed lymphocyte reaction (MLR)-negative) sibling was chosen as donor of PBL for Allo-CMI. At week 8 post-ASCT, as soon as the patient achieved a stable clinical condition (WBC: 2,700/mm3; Hb: 9.1 g %; platelets: 56,000/mm3), the patient received 5×107 T cells/kg of PBL from the HLA-matched sibling. Starting at week 8, on the same day as the administration of the first Allo-CMI treatment, the patient also received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- Patient No. 18.
- This male patient was diagnosed with metastatic breast cancer, with metastases to the bone marrow, sternum and vertebrae T4 to T7. He underwent lumpectomy with axillary lymph node dissection showing involvement of 16/18 lymph nodes. The patient was 36 years old at the time of ASCT. Prior to ASCT, he received a conditioning regimen of carboplatin, 200 mg/m/dlay, days −7 to −4; thiotepa, 60 mg/m2/day, days −6 to −4; etoposide, 200 mg/m2/day, days −5 to −3; and melphalan, 60 mg/M2/day, days −4 to −3.
- ASCT consisted of 1.81×108 peripheral blood stem cells cells/kg, infused IV on
day 0. The stem cells were collected after mobilization with G-CSF (7.5 mg/kg/day for 5 days) using three collections with the CS 3000® Plus blood cell separator. Following ASCT, the patient recovered with no complications and was discharged. - A fully HLA-matched (A, B, DR and mixed lymphocyte reaction (MLR)-negative) brother was chosen as donor of PBL for Allo-CMI. At week 5 post-ASCT, as soon as the patient achieved a stable clinical condition (WBC: 11,000/mm3; Hb: 11.5 g %; platelets: 201,000/mm3), the patient received 2.3×107 T cells/kg of PBL from the HLA-matched brother. Starting at week 5, on the same day as the administration of the first Allo-CMI treatment, the patient aIlso received 6×106 IU of rhIL-2/m2/day for 3 days, by subcutaneous injection. No GVHD has been observed to date.
- Portions of the above-described patient treatment protocols are summarized in Table 1, below. Patients are grouped according to disease (AML, CML, NHL and breast cancer).
TABLE 1a Patient Status Allo Cells No. Pre-ASCT Cond. Regimen Type ASCT (T Cells/Kg) AML: 1 1CR BU/CY ABMT: Purged PBL 104 − 107(day +1 to +47) 2 1CR 13U/CY ABMT: Purged PBL 104 − 107(day +1 to +80) 3 1CR BU/CY ABMT: Non-Purged PBL 107 + IL2 (day +1) 4 1CR BU/CY + TT ABMT: Non-Purged PBL 107 + IL2 (day +1) 6 1CR BU/CY + TT ABMT: Non-Purged 1. PBL 2. PBL + IL2 13 1CR BU/CY + TT ABMT: Non-Purged 1. PBL 14 2PR BU/CY + MX ABMT: Non-Purged 1. PBL 2. Cytoxan/PBL + IL2 15 1CR BU/CY + TT ABMT: Non-Purged 1. PBL CML: 5 CP(Ph−) CY/TBI ABMT: Non-Purged 1. PBL 2. PBL + IL2 3. CAL + IL2 7 CP(Ph+) CY/TBI ABMT: Non-Purged 1. PBL 2. PBL + IL2 NHL: 8 2PR ETACM ABMT + PBSC: Purged 1. PBL 2. PBL + IL2 3. Allogeneic BMT (due to marrow aplasia) 9 2PR ETACM ABMT: Purged 1. PBL 2. PBL + IL2 3. CAL + IL2 10 2CR ETACM ABMT + PBSC: Non-Purged 1. PBL. 2. PBL + IL2 3. CAL + IL2 11 2CR ETACM ABMT + PBSC: Non-Purged 1. PBL 2. PBL 3. PBL 4. PBL + IL2 12 Relapse ETACM ABMT: Non-Purged 1. PBL 2. PBL + IL2 16 2PR ETACM ABMT + PBSC: Non-Purged 1. PBL BREAST CANCER: 17 Metastatic CTEM PBSC: Non-Purged 1. PBL + IL2 18 Metastatic CTEM PBSC: Non-Purged 1. PBL + IL2 - II. Results
- The above-described patients have been followed for various lengths of time. The disease status of the patients is summarized below:
- Patient No. 1 relapsed after 6 months and died at 9 months after ASCT.
- Patient No. 2 relapsed after 12 months and died at 19 months after ASCT.
- Patient No. 3 is alive and well over 34 months after ASCT.
- Patient No. 4 is alive and well over 24 months after ASCT.
- Patient No. 5 is alive and well over 23 months after ASCT, showing no signs of the Philadelphia chromosome (Ph-) by cytogenetic analysis and being negative by PCR for the bcr/abl translocation characteristic of the Philadelphia chromosome. The patient is receiving 9×106 units of IFNα (Roferon A, S.C.) every day.
- Patient No. 6 is alive and well over 23 months after ASCT with no evidence of disease.
- Patient No. 7 is alive and well over 21 months post-ASCT. Currently, the patient is on IFINα treatment, and is hematologically normal with no clinical sign of disease.
- Patient No. 8, currently at nearly 2 years after initial ASCT and over one year following allogeneic BMT, is alive and well with no evidence of lymphoma. The patient has mild cutaneous chronic GVHD with Karnofsky score of 100%
- Patient No.9 was alive and well until 18 months after ASCT. At 19 months he has lymphadenopathy and is being evaluated for relapse.
- Patient No. 10 is alive and well over 15 months after ASCT with no evidence of disease.
- Patient No. 11 is alive and well over 13 months after ASCT with no evidence of disease.
- Patient No. 12 underwent relapse at 3 months post-ASCT and died at 5 months post-ASCT.
- Patient No. 13 underwent relapse at 4 months post-ASCT, before receiving allo-CMI with rhIL2. He is alive and further immunotherapy is planned.
- Patient No. 14 is alive and well with no evidence of disease over 5 months post-ASCT.
- Patient No. 15 is alive and well with no evidence of disease over 4 months post-ASCT.
- Patient No. 16 is alive and well with no evidence of disease 3 months post-ASCT.
- Patient No. 17 is alive and well with no evidence of disease 2 months post-ASCT.
- Patient No. 18 is alive and well with no evidence of disease 1.5 months post-ASCT.
- The results reported above indicate that Allo-CMI and Allo-CCI may be the most rational and practical approaches for eradication of residual malignant cells. GVT effects induced by administration of allogeneic lymphocytes may be further enhanced by administration in vivo of rhIL2.
- Cytokines used in the following experiments were obtained as follows: (1) rhIL2 was provided by Dr. C. R. Franks (EuroCetus BY, Amsterdam, The Netherlands) as a lyophilized powder in 1 mg vials contianing 18×106 international units (IU). (2) Recombinant interferon-gamma (rIFNγ) was provided by Roussel Uclaf (Romainville, France) as a lyophilized powder containing 2×107 U/mg. (3) Recombinant human IL-6 (rIL-6) was kindly provided by Dr. M. Revel and Dr. O. Laub (InterPharm Laboratories, Rehovot, Israel) in a concentration of 1.13 mg/ml protein containing 43×106 IU/ml. (4) Recombinant human IL-7 (rhIL-7) was provided by Pepro Tech (New Jersey, USA) as lyophilized powder and was reconstituted to 100 mg/ml.
- Lymphocytes were preactivated in vitro with rhIL2 or with combinations of rhIL2 and other cytokines for four days at 37° C. Concentrations of cytokines used for in vitro incubation of lymphocytes were as follows: (a) rhIL2: 6000 IU/ml; (b) rIL6: 100-1000 U/ml; (c) rIL7: long/ml; and (d) IFNy: 1000 U/ml. Anti-tumor effects of CAL collected post-culturing were assayed against natural killer (NK)-sensitive K562 tumor cells and NK-resistant Daudi tumor cells. The in vitro toxicity was evaluated by specific chromium release following incubation of effector cells with chromium-labeled tumor cells. Results are presented below as lytic units per 106 effector cells, determined for 30% lysis of 5×103 target cells:
Cytotoxicity (Lytic Units/106 Cells) Anti-Daudi Anti-K562 IL2 alone 48 53 IL2 + IL6 + IL7 + IFNγ 210 129
Claims (19)
1. A method of treating a human cancer patient, said patient having undergone a malignant cell debulking procedure and being at risk for disease relapse due to a population of residual malignant cells that may remain viable in said patient following said debulking procedure, comprising:
a) providing a sample of stem cells from said patient, said sample being suitable for autologous transplantation into said patient;
b) performing an autologous transplant of said patient with said sample;
c) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
d) administering to said patient an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a clinically significant graft-versus-malignant cell response; and
e) monitoring said patient for levels of malignant cells deriving from said population.
2. The method of claim 1 , wherein said regimen comprises the following steps in sequence:
a) treating said patient by administration of about 107 cells/kg to about 109 cells/kgof HLA-compatible, allogeneic peripheral blood lymphocytes;
b) monitoring said patient for indications of a graft-versus-malignant cell response; and
c) if no or insufficient graft-versus-malignant cell response develops in said patient, escalating said treatment by performing at least one procedure selected from the group consisting of (1) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes greater than the number of lymphocytes administered in step (a); (2) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes at least as great as the number of lymphocytes administered in step (a), accompanied by administration of at least one T-cell-activating cytokine to said patient; (3) administration of HLA-compatible, allogeneic CAL's to said patient; and (4) administration of HLA-compatible, allogeneic CAL's, accompanied by administration in vivo of at least one T-cell-activating cytokine to said patient;
wherein more than one of said procedures is performed if no or insufficient graft-versus-malignant cell response develops in said patient following said first or subsequent procedure.
3. The method of claim 2 , wherein step (a) further comprises administration in vivo of at least one T-cell-activating cytokine to said patient.
4. A method of treating a human cancer patient, said patient having undergone a malignant cell debulking procedure and being at risk for disease relapse due to a population of residual malignant cells that may remain viable in said patient following said debulking procedure, comprising:
a) providing a sample of stem cells from said patient, said sample being suitable for autologous transplantation into said patient;
b) performing an autologous transplant of said patient with said sample;
c) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
d) administering to said patient an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a mild graft-versus-host response; and
e) monitoring said patient for levels of malignant cells deriving from said population.
5. The method of claim 4 , wherein said regimen comprises the following steps in sequence:
a) treating said patient by administration of about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes;
b) monitoring said patient for indications of a mild graft-versus-host response; and
c) if no or insufficient graft-versus-host response develops in said patient, escalating said treatment by performing at least one procedure selected from the group consisting of (1) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes greater than the number of lymphocytes administered in step (a); (2) administration of a number of HLA-compatible, allogeneic peripheral blood lymphocytes at least as great as the number of lymphocytes administered in step (a), accompanied by administration of at least one T-cell-activating cytokine to said patient; (3) administration of HLA-compatible, allogeneic CAL's to said patient; and (4) administration of HLA-compatible, allogeneic CAL's, accompanied by administration of at least one T-cell-activating cytokine to said patient;
wherein more than one of said procedures is performed if no or insufficient graft-versus-host response develops in said patient following said first or subsequent procedure.
6. The method of claim 5 , wherein step (a) further comprises administration in vivo of at least one T-cell-activating cytokine to said patient.
7. The method of claim 4 , wherein said regimen comprises the following steps in sequence:
a) administering to said patient about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes and at least one T-cell-activating cytokine to said patient;
b) monitoring said patient for signs of a mild graft-versus-host response;
c) if no or insufficient graft-versus-host response develops in said patient, administering about 107 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic CAL and at least one T-cell-activating cytokine to said patient; and
d) monitoring said patient for signs of a mild graft-versus-host response.
8. The method of claim 4 , wherein said regimen comprises the following steps in sequence:
a) administering to said patient about 105 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic peripheral blood lymphocytes, said HLA-compatible, allogeneic peripheral blood lymphocytes comprising CAL, and at least one T-cell-activating cytokine to said patient;
b) monitoring said patient for signs of a mild graft-versus-host response;
c) if no or insufficient graft-versus-host response develops in said patient, administering about 105 cells/kg to about 109 cells/kg of HLA-compatible, allogeneic CAL and at least one T-cell-activating cytokine to said patient; and
d) monitoring said patient for signs of a mild graft-versus-host response.
9. The method of claim 2 , 3, 5, 6, 7 or 8 wherein said cytokine is selected from the group consisting of IL2, IL4, IL5, IL6, IL7, IFNα, IFNγ and TNFα.
10. The method of claim 4 , wherein said stem cells are obtained from bone marrow.
11. The method of claim 4 , wherein said stem cells are obtained from the peripheral circulation.
12. The method of claim 4 , wherein said stem cells are obtained from fetal sources selected from the group consisting of fetal tissue, fetal circulation and umbilical cord blood.
13. The method of claim 4 , wherein said malignant cells are leukemia cells.
14. The method of claim 4 , wherein said malignant cells are lymphoma cells.
15. The method of claim 4 , wherein said malignant cells are breast cancer cells.
16. The method of claim 1 or 4, wherein said HLA-compatible cells are fully HLA-matched with said patient.
17. The method of claim 1 or 4, wherein said HLA-compatible cells are at least haploidentical with said patient.
18. The method of claim 1 or 4, wherein said HLA-compatible cells are single HLA locus-mismatched cells from a sibling of said patient.
19. An article of manufacture comprising packaging material and a biological cell container within said packaging material, wherein said packaging material contains a label or package insert indicating that said biological cell container and any contents therein are to be used in the method of claim 1 or 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/005,747 US20020176850A1 (en) | 1994-03-17 | 2001-12-03 | Immunotherapy of cancer with allogeneic lymphocytes |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21494494A | 1994-03-17 | 1994-03-17 | |
US65669496A | 1996-06-03 | 1996-06-03 | |
US08/735,496 US5928639A (en) | 1994-03-17 | 1996-10-23 | Immunotherapy of cancer with allogeneic lymphocytes |
US31032599A | 1999-05-12 | 1999-05-12 | |
US10/005,747 US20020176850A1 (en) | 1994-03-17 | 2001-12-03 | Immunotherapy of cancer with allogeneic lymphocytes |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US21494494A Continuation | 1994-03-17 | 1994-03-17 | |
US65669496A Continuation | 1994-03-17 | 1996-06-03 | |
US08/735,496 Continuation US5928639A (en) | 1994-03-17 | 1996-10-23 | Immunotherapy of cancer with allogeneic lymphocytes |
US31032599A Continuation | 1994-03-17 | 1999-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020176850A1 true US20020176850A1 (en) | 2002-11-28 |
Family
ID=22801017
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/714,144 Expired - Lifetime US5843435A (en) | 1994-03-17 | 1995-03-16 | Immunotherapy of cancer with allogeneic lymphocytes |
US08/735,496 Expired - Lifetime US5928639A (en) | 1994-03-17 | 1996-10-23 | Immunotherapy of cancer with allogeneic lymphocytes |
US10/005,747 Abandoned US20020176850A1 (en) | 1994-03-17 | 2001-12-03 | Immunotherapy of cancer with allogeneic lymphocytes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/714,144 Expired - Lifetime US5843435A (en) | 1994-03-17 | 1995-03-16 | Immunotherapy of cancer with allogeneic lymphocytes |
US08/735,496 Expired - Lifetime US5928639A (en) | 1994-03-17 | 1996-10-23 | Immunotherapy of cancer with allogeneic lymphocytes |
Country Status (9)
Country | Link |
---|---|
US (3) | US5843435A (en) |
EP (1) | EP0750505B1 (en) |
JP (1) | JPH09510456A (en) |
AU (1) | AU2100695A (en) |
CA (1) | CA2184352A1 (en) |
DE (1) | DE69533189T2 (en) |
ES (1) | ES2224122T3 (en) |
IL (1) | IL112969A (en) |
WO (1) | WO1995024910A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100111905A1 (en) * | 2006-11-08 | 2010-05-06 | Aldagen,Inc. | Methods for improved engraftment following stem cell transplantation |
US20100129329A1 (en) * | 2006-11-08 | 2010-05-27 | Aldagen, Inc. | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION |
US8617884B2 (en) | 2002-06-28 | 2013-12-31 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
WO1996037208A1 (en) * | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
US5800539A (en) * | 1995-11-08 | 1998-09-01 | Emory University | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease |
AU1394497A (en) * | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US6213127B1 (en) | 1996-07-29 | 2001-04-10 | Emory University | Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity |
JP2002514193A (en) * | 1996-11-15 | 2002-05-14 | バクスター、インターナショナル、インコーポレイテッド | Conditioning for allogeneic stem cell transplantation |
US6428782B1 (en) * | 1997-05-23 | 2002-08-06 | Hadasit Medical Research Services And Development Ltd. | Non-myeloablative tolerogenic treatment |
EP1037643B1 (en) * | 1997-10-10 | 2003-12-03 | Meyer Pharmaceuticals, LLC | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
US20040033230A1 (en) * | 1997-12-24 | 2004-02-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6969518B2 (en) * | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US7598226B2 (en) | 1998-12-28 | 2009-10-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
WO2001040269A2 (en) * | 1999-11-30 | 2001-06-07 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
JP4917201B2 (en) * | 2000-12-04 | 2012-04-18 | 株式会社リンフォテック | Preparations for the prevention and treatment of tumors and various infectious diseases after umbilical cord blood transplantation, formulations for promoting the engraftment of umbilical cord blood stem cells after umbilical cord blood transplantation, formulations for prevention and treatment of tumors and various infectious diseases after umbilical cord blood transplantation, and A method for producing a preparation for engraftment of transplanted cord blood stem cells after cord blood transplantation. |
KR20020060643A (en) * | 2002-06-04 | 2002-07-18 | 김진경 | A method of cancer treatment with other person's immune system |
US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
ES2422193T3 (en) * | 2002-06-28 | 2013-09-09 | Life Technologies Corp | Methods to restore the immune repertoire in patients with immunological defects related to autoimmunity and transplantation of hematopoietic organs or stem cells |
WO2005021734A2 (en) * | 2003-09-02 | 2005-03-10 | University Of Massachussets | Generation of hematopoietic chimerism and induction of central tolerance |
WO2005079755A2 (en) * | 2004-02-12 | 2005-09-01 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
WO2006004592A2 (en) * | 2004-05-28 | 2006-01-12 | Mayo Foundation For Medical Education And Research | Methods for autologous stem cell transplantation |
US9155789B2 (en) * | 2005-04-25 | 2015-10-13 | New York University | Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease |
ES2613957T3 (en) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Antibodies against ERBB2 |
CA2660102C (en) | 2006-08-07 | 2017-02-21 | Pdl Biopharma, Inc. | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
SI2641601T1 (en) | 2006-08-07 | 2016-11-30 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib |
KR20120054018A (en) * | 2009-08-17 | 2012-05-29 | 도꾜 다이가꾸 | Pharmaceutical composition containing transiently surviving ctl |
BR112014015959A8 (en) | 2011-12-22 | 2017-07-04 | Yeda Res & Dev | method for treating an individual in need of a non-syngeneic cell graft or tissue, method for treating an individual in need of an immature hematopoietic cell transplantation, method for inducing donor specific tolerance in an individual in need of a cell non-syngeneic or tissue graft, and method for treating an individual who needs a non-syngeneic cell or tissue graft |
WO2016054354A1 (en) | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
US10300090B2 (en) | 2017-03-15 | 2019-05-28 | Orca Biosystems, Inc. | Compositions of hematopoietic stem cell transplants |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928639A (en) * | 1994-03-17 | 1999-07-27 | Hadasit Medical Research Services And Development Ltd. | Immunotherapy of cancer with allogeneic lymphocytes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4861589A (en) * | 1987-03-23 | 1989-08-29 | Trustees Of Boston University | Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells |
US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
JPH07102131B2 (en) * | 1991-07-15 | 1995-11-08 | 日本石油株式会社 | Method for enhancing cytotoxicity of human lymphocytes against cancer cells |
-
1995
- 1995-03-13 IL IL11296995A patent/IL112969A/en not_active IP Right Cessation
- 1995-03-16 US US08/714,144 patent/US5843435A/en not_active Expired - Lifetime
- 1995-03-16 DE DE69533189T patent/DE69533189T2/en not_active Expired - Lifetime
- 1995-03-16 WO PCT/US1995/003303 patent/WO1995024910A1/en active IP Right Grant
- 1995-03-16 EP EP95913730A patent/EP0750505B1/en not_active Expired - Lifetime
- 1995-03-16 JP JP7524180A patent/JPH09510456A/en active Pending
- 1995-03-16 CA CA002184352A patent/CA2184352A1/en not_active Abandoned
- 1995-03-16 AU AU21006/95A patent/AU2100695A/en not_active Abandoned
- 1995-03-16 ES ES95913730T patent/ES2224122T3/en not_active Expired - Lifetime
-
1996
- 1996-10-23 US US08/735,496 patent/US5928639A/en not_active Expired - Lifetime
-
2001
- 2001-12-03 US US10/005,747 patent/US20020176850A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928639A (en) * | 1994-03-17 | 1999-07-27 | Hadasit Medical Research Services And Development Ltd. | Immunotherapy of cancer with allogeneic lymphocytes |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617884B2 (en) | 2002-06-28 | 2013-12-31 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US20100111905A1 (en) * | 2006-11-08 | 2010-05-06 | Aldagen,Inc. | Methods for improved engraftment following stem cell transplantation |
US20100129329A1 (en) * | 2006-11-08 | 2010-05-27 | Aldagen, Inc. | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION |
Also Published As
Publication number | Publication date |
---|---|
EP0750505A1 (en) | 1997-01-02 |
DE69533189T2 (en) | 2005-07-21 |
US5928639A (en) | 1999-07-27 |
IL112969A (en) | 2001-05-20 |
MX9604099A (en) | 1997-09-30 |
US5843435A (en) | 1998-12-01 |
ES2224122T3 (en) | 2005-03-01 |
WO1995024910A1 (en) | 1995-09-21 |
JPH09510456A (en) | 1997-10-21 |
CA2184352A1 (en) | 1995-09-21 |
AU2100695A (en) | 1995-10-03 |
IL112969A0 (en) | 1995-06-29 |
DE69533189D1 (en) | 2004-07-29 |
EP0750505B1 (en) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5928639A (en) | Immunotherapy of cancer with allogeneic lymphocytes | |
EP0831860B1 (en) | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation | |
Giralt et al. | CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation | |
Verneris et al. | Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma | |
AU707211B2 (en) | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease | |
US6544787B1 (en) | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation | |
Bacigalupo et al. | Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation | |
Carella et al. | Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. | |
Brune et al. | Remission maintenance therapy with histamine and interleukin‐2 in acute myelogenous leukaemia | |
Mastino et al. | Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice | |
Slavin | New strategies for bone marrow transplantation | |
Bacigalupo et al. | Collection of peripheral blood hematopoietic progenitors (PBHP) from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony-stimulating factor | |
Glass et al. | Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation | |
Bai et al. | Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy | |
WO2019028337A1 (en) | Treating and inhibiting leukemia with nk-92 cells | |
US7544355B2 (en) | Methods and compositions for allogeneic transplantation | |
Dubinett et al. | Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma | |
Da et al. | Autologous bone marrow mixed with HLA-haploidentical allogeneic marrow transplantation for treatment of patients with malignant blood diseases | |
US6213127B1 (en) | Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity | |
JP4106488B2 (en) | Use of stem cells and CD6-depleted stem cells for induction of immune tolerance against allografts and / or treatment of leukemia | |
Weiss et al. | Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia | |
MXPA96004099A (en) | Immunotherapy of cancer with lymphocytes alogeni | |
Gürman | Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic cell transplantation with myeloablative conditioning | |
Kloosterman | Graft-versus-leukemia: applicable in the treatment of leukemia with bone marrow transplantation?: preclinical studies in rat models relevant for human acute leukemia | |
Soiffer et al. | Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |